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ABSTRACT 
The inability of articular cartilage to repair itself after acute injury has been 
implicated in the development of osteoarthritis. The objective of this work was to develop 
methods for delivering growth factors to cartilage and to test the ability of a self-
assembling peptide scaffold, (KLDL)3, with or without growth factors to augment repair. 
Delivery methods included growth factor adsorption, scaffold-tethering, and modification 
of growth factor structure. 
(KLDL)3 was modified to deliver IGF-1 and TGF-β1 to chondrocytes and bone-
marrow-derived stromal cells (BMSCs), respectively, by adsorption and by biotin-
streptavidin tethering. This study showed that while TGF-β1 can be effectively delivered 
by adsorption, IGF-1 can not. Additionally, while tethering these factors provided long-
term sequestration, tethering did not stimulate proteoglycan production in vitro. 
A full-thickness, critically sized, rabbit cartilage defect model was used to test the 
ability of (KLDL)3 with or without chondrogenic factors (TGF-β1, dexamethasone, and 
IGF-1) and BMSCs to stimulate cartilage regeneration in vivo. (KLDL)3 alone showed 
the greatest repair after 12 weeks with significantly higher Safranin-O, collagen II 
immunostaining, and cumulative histology scores compared to untreated contralateral 
controls. Ongoing studies include the evaluation of (KLDL)3 in a clinically relevant sized 
equine defect co-treated with microfracture and subjected to strenuous exercise.  
A fusion protein was created by adding a heparin-binding domain to IGF-1 (HB-
IGF-1), converting IGF-1 from a short-acting growth factor to one that can be retained 
and locally delivered in articular cartilage in vivo. It was shown that HB-IGF-1 is retained 
in cartilage through binding to negatively charged glycosaminoglycan chains, with 
chondroitin sulfate the most prevalent type in cartilage. HB-IGF-1 was shown to bind 
adult human cartilage and to be preferentially delivered and retained in rat articular 
cartilage after intra-articular injection. In contrast, unmodified IGF-1 was not detectable 
after intra-articular injection. These results suggest that modification of growth factors 
with heparin-binding domains may be a clinically relevant strategy for local delivery to 
cartilage. 
Taken together, these results show that (KLDL)3 self-assembling peptide 
hydrogels are customizable for growth factor delivery and can promote cartilage repair in 
vivo. In addition, the fusion protein HB-IGF-1 is preferentially retained in cartilage tissue 
compared to un-modified IGF-1. 
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Chapter 1. Introduction 
 
 
1.1 Cartilage Biology 
Adult articular cartilage is composed of one cell type, the chondrocyte, which accounts 
for approximately 1-5% of the tissue volume with the remaining filled by extracellular 
matrix (ECM) (15-40%) and water (60-85%)20, 47, 51, 60. Cells maintain a spherical 
morphology, though somewhat flattened in the superficial zone, and do not directly 
contact other cells58. Cartilage lacks a nervous and vascular supply, resulting in 
chondrocytes in adult articular cartilage remaining relatively inactive metabolically and 
having a poor repair capacity20, 48.  
 
Chondrocytes synthesize all ECM components, which include collagens (10-30% wet 
wt), proteoglycans (PGs) (3-10% wet wt), and non-collagenous proteins and 
glycoproteins51, 60. The collagen network provides tensile strength and helps to retain 
proteoglycans, which offer compressive resistance. Type 2 collagen is the predominant 
type found in articular cartilage with types 9 and 11 incorporated within the basic 
structure of this heteropolymer13. The major PG in the extracellular matrix is aggrecan, 
which consists of a protein backbone to which glycosaminoglycan (GAG) side chains of 
chondroitin sulfate (CS) and keratan sulfate (KS) are covalently attached60. The 
negatively charged GAGs of the PGs give cartilage its high fixed-charge density, 
controlling ionic equilibrium in the tissue50. Aggrecan molecules bind non-covalently to 
hyaluronic acid (HA) chains, stabilized by link protein26. Chondrocytes are directly 
surrounded by a pericellular matrix about 2 µm wide58 composed of molecules that can 
14 
interact with the cell including type 6 collagen, HA, a heparan sulfate and chondroitin 
sulfate containing proteoglycan (perlecan), and decorin57. 
 
1.2 Cartilage Pathogenesis and the Current Strategies for Repair 
Cartilage injuries generally occur when the knee is impacted or subjected to sudden 
twisting, often concurrent with meniscal or ligament tears6, 27. These types of injuries 
occur in both children and adults55, with roughly 3 million knee injuries reported each 
year in the United States1. These injuries result in an acute inflammatory environment 
(presence of IL-1β, TNF-α, IL-6, among others) in the joint, which dissipates after 1-2 
weeks30, but remains elevated above normal levels for months to years4, 44, 45. These 
changes in cytokine levels, in combination with changes in loading of the joint69, are 
implicated in the progression of a majority of people who sustain these injuries to 
develop osteoarthritis (OA) within 10-20 years24, 45.  
 
OA is a musculoskeletal disorder and the most common form of arthritis, affecting 21.5% 
of the U.S. population20, 73. The disease is characterized by progressive destruction of 
articular cartilage; symptoms include pain and impaired joint movement leading to 
disability20. Current treatments include drug therapy for pain relief, surgical approaches 
(e.g., microfracture, drilling, and mosaic-plasty), biological approaches (e.g., autologous 
chondrocyte implantation (ACI)), and as a final recourse, joint replacement. None of 
these treatments has yielded lasting results or regeneration of tissue equivalent to normal 
cartilage20, 60. Microfracture, which creates hemorrhage to induce the migration of 
potential repair cells, results in fibrocartilage tissue that is bio-mechanically inferior to 
15 
native tissue65. ACI is not indicated for the treatment of cartilage damage associated with 
OA and results have not been shown to be significantly different than microfracture 
treatment when used to repair focal defects within joint surfaces32, 38. Joint replacement is 
currently the only option for severe articular cartilage degeneration; however, it is not a 
permanent solution and often, additional surgery is required. Recently it has been shown 
in vitro that it is possible for cartilage explants to recover from initial aggrecanase-
mediated GAG loss but not from collagen loss35, 59. This suggests that early intervention 
following cartilage injuries may be key to halting progression to OA, likely with a 
combination of anabolic, anti-catabolic, and defect-filling treatments45. 
 
1.3 Cartilage Tissue Engineering 
In 1997, a panel held by the National Science Foundation defined tissue engineering as 
“… the application of the principles and methods of engineering and life sciences toward 
the fundamental understanding of structure-function relationships in normal and 
pathological mammalian tissue and the development of biological substitutes to restore, 
maintain, or improve function39”. From the previous section, this suggests that cartilage 
repair may be improved (1) by augmenting native repair attempts through filling defects 
in situ or (2) by implanting more mature constructs grown in vitro and developing 
methods for integrating this engineered tissue with native tissue27. In the case of (1), this 
could be particularly beneficial in combination with marrow stimulation techniques in 
that larger defect sizes may be able to be treated when an external scaffold is supplied to 
encourage cellular infiltration and differentiation. This strategy will be the focus of this 
thesis work. Many groups have begun efforts towards the development of tissue-
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engineered cartilage; however the growth of cartilage that is comparable to native tissue 
and is able to successfully integrate with native tissue has not yet been achieved (see 8, 18, 
28, 41, 67 for review). The challenge for successful tissue engineering remains the discovery 
of an optimal combination of scaffold, biological signaling, and cells for tissue 
regeneration that is also practical for clinical use. 
 
The scaffold should ideally serve as a microenvironment that promotes ECM production 
by either endogenous or exogenous cells. A variety of natural and synthetic materials 
have been proposed for use in cartilage tissue engineering. As some of the few materials 
approved by the Food and Drug Administration (FDA) for use in the body, polyglycolic 
acid (PGA), polylactic acid (PLA), and polylactic-co-glycolic acid (PLGA) have been 
widely investigated, but these polymers degrade quickly in the body and have been 
shown to produce toxic monomers70. Natural polymers that undergo enzymatic 
hydrolysis, such as hyaluronic acid, collagen, fibrin, and chitin have also been used in a 
variety of combinations as scaffolds28, 70. While these natural materials are all able to 
support maintenance of the chondrocyte phenotype, none has been shown to be an ideal 
substrate for cartilage formation with biochemical and mechanical properties comparable 
to native tissue. Hydrogels are an appealing scaffold choice due to their high water 
content, similar to the articular cartilage environment. This attribute also allows for the 
encapsulation of chondrocytes and proteins within the network, and these gels have been 
shown to maintain the spherical morphology and gene expression of chondrocytes74. 
Hydrogels have been developed from alginate, polyethyleneglycol (PEG), chondroitin 
sulfate, self-assembling peptides, and other materials41. 
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Self-assembling peptides offer the opportunity to create customizable scaffolds that can 
be induced to assemble upon placement in a physiological environment. In addition, 
scaffolds composed of nanofibers have been shown to produce better outcomes than 
microfiber-based scaffolds42. The family of self-assembling peptides all satisfies the 
principle that there is no net charge, but an equal number of ionizable basic and acidic 
amino acids that promote β-sheet formation upon self-assembly, which can be initiated 
by a solution at physiological pH and ionic strength36. The peptide KLD is composed of 
the sequence AcN-KLDLKLDLKLDL-CNH2 and is based on the work of Zhang et al.75, 
76. KLD has been demonstrated to support the synthesis and accumulation of cartilage-
like ECM by embedded chondrocytes36 and bone marrow derived stromal cells 
(BMSCs)37, 40.  
 
This peptide also offers flexibility in design that allows for the opportunity of growth 
factor delivery for local, specific, prolonged biological stimulation – key to achieving 
optimal tissue induction, especially since growth factors typically have a short half-life 
once they are introduced into the body. A variety of growth factors have been shown to 
be important in chondrogenesis and in stimulation of matrix production by chondrocytes, 
including: TGF-β1, IGF-1, and members of the BMP and GDF families (see 66 for 
review). Recently, Davis et al. developed a system for tethering IGF-1 to another self-
assembling peptide, RAD16-II, by a “biotin-sandwich” technique9. By adding a biotin 
linkage to the end of the peptide sequence and incorporating a minority of this 
biotinylated peptide in a solution of un-modified peptide, self-assembly was not 
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disrupted. This allowed for the attachment of biotinylated IGF-1 molecules through the 
inclusion of streptavidin. This system provided controlled delivery of IGF-1 to 
myocardial tissue in vivo. The non-specific “biotin-sandwich” strategy should be able to 
be applied to other self-assembling peptides such as KLD and offers the potential for 
multiple growth factors to be incorporated into a hydrogel for local tissue delivery. 
 
The final parameter to be considered for successful tissue engineering is cell source.  
There are three main types of cells that have been considered for use in cartilage tissue 
engineering: primary chondrocytes, adult bone-marrow-derived stromal cells (BMSCs), 
and embryonic stem cells. There is a limited availability of primary chondrocytes in adult 
cartilage, and expansion in culture often leads to de-differentiation41, 70. Embryonic stem 
cells, while offering great potential for the differentiation into multiple cell types, are 
associated with many ethical and safety concerns. Therefore, adult BMSCs may present 
the best choice for the future of cartilage tissue engineering. Autologous BMSCs are 
obtainable from a patient’s own bone marrow, and they have been shown to be able to 
undergo expansion and chondrogenesis without risk of tumorigenesis28, 41, 49, 70. Much 
current research is being directed towards the development of optimal expansion and 
differentiation conditions12, 20, 28, 29, 41, 49, 60. 
 
1.4 Insulin-like Growth Factor – I 
IGF-1 plays a primary role in cartilage homeostasis by stimulating PG synthesis, 
promoting cell survival, and inhibiting cartilage degradation. IGF-1 is produced primarily 
by the liver, but other cell types, including chondrocytes, are also able to synthesize IGF-
19 
1. In cartilage, IGF-1 can act both in a paracrine and autocrine manner52. It is a basic, 7.6 
kDa protein that binds the IGF-1 receptor (IGF-1R) with a KD of 0.2-1 nM34. IGF-1Rs 
exist on the cell surface as disulfide-linked dimers and studies have shown that a single 
molecule of IGF-1 is able to activate the receptor64 with approximately 10,000 receptors 
on the surface of each chondrocyte5. Human OA chondrocytes express and produce 
increased levels of IGF-1 but are hypo-responsive to it52. An explanation for this may be 
the increased production of IGF binding proteins (IGFBPs), which can associate with the 
cell surface or ECM and may be responsible for decreased amounts of IGF-1 available to 
bind IGF-1Rs. Therefore, IGF-1 growth-factor or gene therapy offers a potential 
treatment for diminished IGF-1 activity, but to be effective, amounts of IGF-1 delivered 
within the joint must exceed the binding capacity of local IGFBPs10. 
 
IGF-1 has also been used as treatment in a variety of cartilage injury models. Inclusion of 
IGF-I in fibrin-chondrocyte constructs enhanced chondrogenesis in equine cartilage 
defects, including incorporation into surrounding cartilage14. Cartilage explants treated 
with IL-1 were partially rescued from proteoglycan degradation by co-culture with 
synovial cells transduced with AdIGF-154. Madry et al. demonstrated that chondrocytes 
transfected with AdIGF-1 included in alginate scaffolds can enhance repair of rabbit 
cartilage defects46. In addition, Goodrich et al. transplanted equine chondrocytes 
genetically modified with AdIGF-1 into equine femoral trochlea defects and found that 
repair of the defect with hyaline-like cartilage was accelerated22. Direct injections of 
AdIGF-1 into the metacarpophalangeal (MCP) joints of horses were also shown to result 
in significant elevations of IGF-I in synovial fluid for approximately 21 days with 
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minimal detrimental effects21. A critical factor that must be considered in any IGF-1 
delivery strategy is that systemic delivery of IGF-1 can cause significant side effects31 as 
well as the potential to promote diabetic retinopathy72 and cancer7. These studies suggest 
that IGF-1 is a critical component of cartilage repair, yet an optimal delivery technique 
has yet to be developed. 
 
1.5 In vivo Animal Models 
While in vitro cell work is important for the initial screening and development of tissue-
engineered products, the effectiveness of constructs in vivo must also be considered. To 
this end, several animal models have been used for the testing of constructs designed to 
regenerate cartilage. Typically, the initial screening for the safety and in vivo efficacy of 
such constructs are performed in a small animal model. Nude mice have been used for the 
testing of cartilage growth potential by subcutaneous implantation2, 33, 56, 62, 63, however, 
this model does not allow for immunological screening of potential constructs nor does it 
evaluate the ability for healing of a cartilage defect or for the ability to integrate with 
native tissue. An alternative immuno-competent small animal model is the rabbit. Rabbits 
offer many of the same advantages of mice in that they are available at low cost with 
minimal housing requirements. Appropriate defect models in weight-bearing areas of the 
medial femoral condyles of rabbit knee joints have been developed for the testing of 
tissue-engineered constructs11, 17, 23, 61.   
 
Once basic testing has been completed, true construct functionality must be evaluated in a 
large animal model such as a dog, sheep, goat, pig, or horse. While no defect model is 
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directly applicable to humans due to physiological and anatomical differences between 
the human joint and model animal joints28, the horse seems to most closely approximate 
human cartilage based on the thickness of its articular cartilage16, its susceptibility to 
osteoarthritis15, and similar cartilage biochemical composition68.  A model for inducing 
OA in equines has been developed15, and several studies have used manufactured defects 
as models for testing cartilage repair strategies3, 43, 53, 71.  It must be kept in mind, 
however, that positive results obtained from in vivo animal testing must be viewed with 
caution as they are not necessarily predictive of success in humans19, 25. 
 
1.6 Thesis Outline 
The objective of this work was to develop methods for delivering growth factors to 
cartilage and to test the ability of a self-assembling peptide scaffold, (KLDL)3, with or 
without growth factors to augment repair. Delivery methods included growth factor 
adsorption, scaffold-tethering, and modification of growth factor structure. 
 
In Chapter 2, IGF-1 and TGF-β1 were adsorbed and tethered to the self-assembling 
peptide scaffold KLD and the effects on matrix production by chondrocytes and BMSCs, 
respectively, were observed.  
 
In Chapter 3, the effects of KLD, chondrogenic factors, and allogeneic BMSCs on the in 
vivo repair of a critically sized full-thickness rabbit cartilage defect were examined.  
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In Chapter 4, binding of a novel fusion protein, heparin-binding IGF-1 or HB-IGF-1, in 
cartilage tissue was investigated. The mechanism by which HB-IGF-1 is retained in 
cartilage was examined and the ability of HB-IGF-1 to provide sustained growth factor 
delivery to cartilage in vivo and to human cartilage explants was determined. 
 
Finally, in Chapter 5, the main findings and conclusions are discussed and new questions 
motivated by this thesis are explored. 
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Chapter 2. Growth Factor Delivery via Self-assembling Peptide 
Scaffolds 
 
The optimal strategy for delivering growth factors to cells for the purpose of cartilage 
tissue engineering remains an unmet challenge. The purpose of this study was to engineer 
self-assembling peptide scaffolds (i.e., (KLDL)3 or KLD) to deliver growth factors to 
encapsulated cells. Chondrocytes or bone marrow stromal cells were encapsulated in 
KLD with or without IGF-1 or TGF-β1, respectively. The growth factors were either (1) 
pre-mixed with peptide solution prior to assembly to adsorb them to KLD, or (2) tethered 
to KLD through biotin-streptavidin bonds. Fluorescently tagged streptavidin was used to 
determine IGF-1 kinetics; sGAG and DNA content was measured. Tethering IGF-1 to 
KLD significantly increased retention of IGF-1 in KLD compared to adsorption, but 
neither method increased sGAG or DNA accumulation above control. Adsorbing TGF-β1 
significantly increased proteoglycan accumulation above control, but again, tethering did 
not affect sGAG levels. Increasing the amount of tethered TGF-β1 negatively impacted 
DNA levels. This study provided an initial evaluation of methods for delivering growth 
factors to cells within a KLD hydrogel scaffold and showed that while TGF-β1 can be 
effectively delivered by adsorption, IGF-1 can not. Additionally, while tethering these 
factors provided long-term sequestration, tethering was not effective in stimulating 
proteoglycan production. Self-assembling peptides are a clinically relevant material that 
can be injected in vivo. While tethering growth factors to KLD results in long-term 
delivery, tethering does not result in the same bioactivity as soluble delivery, indicating 
that presentation of proteins is vital when considering a delivery strategy.  
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2.1 Introduction  
Acute cartilage defects remain a challenge to repair. Currently, interventions such as 
microfracture or autologous chondrocyte implantation remain the standard of care25, but 
these methods still result in mechanically inferior repair tissue15. Cartilage tissue 
engineering has emerged as a possible avenue for improving repair. As such, many 
combinations of scaffolds, cells, and growth factors have been proposed.  
 
Growth factors including TGF-β1, IGF-1, and members of the GDF and BMP families 
are known to be important in inducing repair, attracting migration of repair cells, and 
stimulating chondrogenesis, proliferation, and production of matrix5, 43, 44. Due to the 
reality that growth factors act on multiple tissues and can have detrimental side effects if 
applied systemically, local delivery is necessary. Although intra-articular injections may 
present a simple approach for delivery directly to the joint, often much higher than 
physiologic concentrations must be used along with multiple injections in order to 
overcome the fact that growth factors have short half-lives and may be cleared rapidly 
from the synovial fluid. Therefore, delivery methods using scaffolds have been proposed 
to protect growth factors from degradation and to deliver them over longer periods of 
time45. Despite the advantages hydrogels offer as scaffolds, growth factors quickly 
diffuse out of them28. Therefore, most successful delivery strategies to date have 
incorporated growth factor-loaded microspheres within the hydrogel, so that release of 
the factors can be controlled by the degradation rate of the microspheres43. While this has 
shown positive results, high loading concentrations of growth factors within these 
microspheres are still required. This creates the possibility of high localized doses 
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through initial bolus release in vivo, which is particularly dangerous for TGF-β1 since it 
has been shown to cause side effects such as inflammation and osteophyte formation3. 
  
Hydrogel scaffolds made from the self-assembling peptide sequences (RADA)4 and 
(KLDL)3, which we refer to as RAD and KLD, respectively, have been shown to support 
maintenance of the chondrocyte phenotype24, 34 and chondrogenesis of bone marrow 
stromal cells26. These peptides assemble into hydrogels upon contact with solutions of 
physiologic pH and ionic strength49, enabling them to be injected into tissues in vivo, 
where they have been shown to encourage cell infiltration7. In addition, bioactive 
sequences have been appended to the RAD sequence without disrupting assembly14, 17, 47. 
RAD has also been shown to support growth factor delivery: PDGF-BB and other 
proteins have been adsorbed to RAD18, 27, SDF-1 was inserted directly onto the RAD 
peptide sequence39, and IGF-1 was tethered to RAD through biotin-streptavidin-biotin 
bonds8. 
 
The purpose of this study was to engineer the self-assembling peptide, KLD, to deliver 
the growth factors IGF-1 and TGF-β1 to encapsulated chondrocytes or bone marrow 
stromal cells (BMSCs), respectively, in the context of cartilage tissue engineering. The 
growth factors were either (1) pre-mixed with the peptide solution prior to assembly to 
adsorb them to the hydrogel, or (2) tethered to the hydrogel with high-affinity prior to 
assembly8.  
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2.2 Materials and Methods  
Materials: KLD peptide with the sequence AcN-(KLDL)3-CNH2 and biotinylated-KLD 
(bKLD) peptide with the sequence biotin-(aminocaproic acid)3-(KLDL)3 was synthesized 
by the MIT Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A 
peptide synthesizer with FMOC protection or received as a gift from 3DM (3DM, Inc., 
Cambridge, MA). Biotin-conjugated IGF-1 (bIGF-1) (immunological and biochemical 
testsystems GmbH, Reutlingen Germany) and biotin-conjugated TGF-β1 (bTGF-β1) 
(R&D Systems, Minneapolis, MN) were purchased and used as described below. 
 
Chondrocyte Isolation and Encapsulation: Chondrocytes were isolated from 1-2 week 
old bovine calves (Research 87, Marlborough, MA) as described previously38. 
Chondrocytes were encapsulated in KLD using acellular agarose molds to initiate self-
assembly as outlined below26, resulting in 6mm diameter, 50 µL peptide gel disks. To 
verify bioactivity of bIGF-1, chondrocytes were encapsulated at 12x106 cells/mL in KLD 
peptide (0.35% w/v) alone and cultured in IGF-1-free basal medium supplemented with 
either soluble IGF-1 (PeproTech Inc., Rocky Hill, NJ), soluble bIGF-1, or soluble bIGF-
1/streptavidin at indicated concentrations (ng/mL); n=3-4. Basal medium consisted of 
serum-free high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad, CA) supplemented with 0.003% ITS+1 (Sigma-Aldrich, St. Louis, MO), 1 mM 
sodium pyruvate, 10 mM HEPES buffer, 0.1 mM nonessential amino acids, 0.4 mM 
proline, 20 µg/mL ascorbic acid, 100 units/mL penicillin, 100 µg/mL streptomycin, and 
0.25 µg/mL amphotericin B. This choice of concentration of ITS+1 is equivalent to 5 nM 
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insulin, termed mini-ITS2, 30, and chosen in order to avoid cross-talk of insulin with the 
IGF-1 receptor.  
 
For high-affinity tethering of IGF-1, control, soluble, and tethered gels were created by 
pre-mixing KLD peptide (0.35% w/v) with 0.0035% w/v bKLD and encapsulating 
chondrocytes at 3x106 cells/mL; n=4. For tethered gels, bIGF-1 and fluorescent 
streptavidin-AlexaFluor 488 (Invitrogen) were pre-mixed at equimolar concentrations 
and added to the KLD/bKLD mixture prior to adding cells. For adsorbed gels, bIGF-1 
and fluorescent-streptavidin were pre-mixed as for the tethered gels, but no bKLD was 
used in this case. Chondrocyte gels were cultured in basal medium and supplemented 
with soluble IGF-1 for the soluble condition (soluble IGF-1 replenished at each medium 
change). 
 
BMSC Isolation: Bone marrow was harvested from 1-2 week old bovine calves 
(Research 87) and stromal cells (BMSCs) were isolated as described previously6, 26. 
BMSCs were selected via differential adhesion and expanded two passages in low 
glucose-DMEM with 10% ES-FBS (Invitrogen), 10mM HEPES, 100 units/mL penicillin 
G, 100 µg/mL streptomycin, 0.25 µg/mL amphotericin B, and 5 ng/mL FGF-2 (R&D 
Systems). 
 
BMSC Encapsulation: BMSCs were encapsulated in KLD mixtures at 3x106 cells/mL 
using acellular agarose molds to initiate self-assembly26. For no TGF (n=8) and soluble 
TGF (n=12) conditions, BMSCs were encapsulated in KLD peptide (0.35% w/v) alone. 
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For adsorbed gels (n=16), 0.35% KLD was pre-mixed with 100 ng/mL TGF-β1 (R&D 
Systems) and 100 nM dexamethasone (Sigma-Aldrich, St. Louis, MO) prior to adding 
cells. For tethered gels (n=4), 0.35% w/v KLD was pre-mixed with 0.0035% w/v bKLD, 
2.1 µg/mL streptavidin (Pierce Biotechnology, Rockford, IL) and 100 or 500 ng/mL 
bTGF-β1 prior to adding cells. The resulting 6mm diameter, 50 µL peptide gel disks were 
cultured in high glucose-DMEM (Invitrogen) supplemented with 1% ITS+1 (Sigma-
Aldrich), 1 mM sodium pyruvate,  37.5 µg/mL ascorbate-2-phosphate (Wako Chemicals, 
Richmond, VA), PSA (100 U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 µg/mL 
amphoteracin), 10 mM HEPES, 0.4 mM proline, and 0.1 mM non-essential amino acids. 
Soluble gels had additional supplementation of 10 ng/mL recombinant human TGF-β1 
(R&D Systems) (replenished at each medium change). No TGF, soluble, and tethered 
gels had additional supplementation of 100 nM dexamethasone (replenished at each 
medium change). 
 
Cell Viability and Cell-Seeded Hydrogel Biochemistry: Viability was determined by 
staining with FDA (live) and ethidium bromide (dead). There were no differences in 
viability among conditions for chondrocyte or BMSC experiments, and all experiments 
had >75% viability. At each timepoint, gels were digested with 250 µg/mL proteinase-K 
(Roche Applied Science, Indianapolis, IN) overnight at 60 ºC. sGAG in each hydrogel 
sample was assessed via DMMB dye binding12; DNA was quantified by Hoechst dye 
assay23. For chondrocyte gels, digests were analyzed for presence of fluorescent 
streptavidin via fluorometer reading at 485/535 nm.  
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Statistical Analyses: All data are presented as mean ± standard error of the mean (SEM). 
Chondrocyte data were analyzed by one-way ANOVA at each timepoint. BMSC data 
were analyzed using a mixed model of variance at each timepoint with animal cell-source 
as a random factor. Residual plots were constructed for dependent variable data to test for 
normality and data were log transformed if necessary to satisfy this assumption. Post hoc 
Tukey tests for significance of pairwise comparisons were performed with a threshold for 
significance of p<0.05. 
 
2.3 Results  
IGF-1 can be tethered to peptide hydrogels: Using a biotin-sandwich approach as 
previously described for a related peptide sequence, RAD8, we tethered IGF-1 to KLD 
scaffolds by including 1:100 ratio by weight of biotinylated KLD (bKLD):KLD and pre-
mixing streptavidin with a biotinylated version of the growth factor (bIGF-1). Multivalent 
streptavidin and bIGF-1 were mixed in equimolar amounts so that the predominant 
complex formed would consist of a single biotinylated growth factor bound to a single 
streptavidin molecule, allowing streptavidin to bind bKLD with one of its three 
remaining binding sites. Excess bKLD (>130:1 molar ratio bKLD:streptavidin) was used 
to ensure that all of the delivered growth factor was tethered. To validate this tethering 
approach relative to simple adsorption, we used fluorescently tagged streptavidin to track 
the streptavidin/bIGF-1 complex in peptide hydrogels with encapsulated chondrocytes. 
Although adsorbed and tethered gels were loaded with equivalent amounts of 
streptavidin/bIGF-1, tethered gels retained significantly more bIGF-1 immediately after 
encapsulation (Fig 2.1A). After one day, adsorbed streptavidin/bIGF-1 had decreased to 
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10-17% of the day 0 levels, and by day 8 it was only 2-6% of day 0 (Fig 2.1B,C). 
Tethering allowed amounts to remain at 20-27% of the day 0 levels even by day 8 (Fig 
2.1B,C). In contrast, when TGF-β1 is adsorbed to KLD peptide hydrogels ~40% is 
retained at day 21 (data not shown).  
 
bIGF is biologically active: To ensure that bIGF-1 had the same biological activity as 
normal IGF-1, chondrocytes encapsulated in KLD were stimulated with 100 ng/mL of 
soluble bIGF-1 or soluble IGF-1 for 4 days. sGAG content of the gels treated with IGF-1 
and bIGF-1 was shown to be equivalent, and both conditions produced significantly more 
sGAG than gels incubated without IGF-1 (Fig 2.2A). DNA content was not significantly 
different among the treatments (Fig 2.2B). In addition, 100 ng/mL of soluble bIGF-1 was 
compared to soluble complexes of 100 ng/mL bIGF-1 pre-mixed with an equimolar 
amount of streptavidin to rule out any effect of binding to streptavidin on sGAG 
production. Again, after 4 days, bIGF-1 with and without streptavidin produced 
equivalent amounts of sGAG, significantly more than gels incubated without IGF-1 (Fig 
2.2C), and DNA was equivalent among the treatments (Fig 2.2D). The bioactivity of 
bTGF-β1 was also confirmed in similar experiments (data not shown). 
 
Adsorbed and Tethered IGF-1 with chondrocytes: Next, bIGF-1/streptavidin 
complexes were either adsorbed to KLD prior to chondrocyte encapsulation or tethered to 
KLD prior to encapsulation. Concentrations of bIGF-1 in the KLD hydrogel were varied 
for the adsorbed and tethered conditions such that cells would be exposed to amounts 
known to stimulate proteoglycan synthesis (>50 ng/mL)13. Although concentrations up to 
36 
1000 ng/mL were tested for adsorbed and tethered bIGF-1, neither method of delivering 
IGF-1 was able to stimulate sGAG production over no IGF-1 levels. This outcome for 
adsorption of IGF-1 is consistent with Fig 1, which showed adsorbed bIGF-1/streptavidin 
rapidly diffused out of KLD (Fig 2.3A). But the lack of bioactivity for tethering was 
unexpected since sufficient levels were present throughout the culture period. Gels 
treated with 50 ng/mL and 300 ng/mL of soluble IGF-1 produced significantly greater 
amounts of sGAG than control IGF-1-free gels at all timepoints, as expected (Fig 2.3A). 
DNA levels increased over time but were not different than control IGF-1-free gels for 
any treatment at any timepoint (Fig 2.3B).  
 
Adsorbed and Tethered TGF-β1 with BMSCs: We next tested the hypothesis that 
since TGF-β1 adsorbed more strongly than IGF-1, it would result in greater proteoglycan 
stimulus than no TGF-β1; we also investigated whether tethered TGF-β1 would promote 
proteoglycan synthesis. BMSCs were stimulated with either soluble TGF-β1 and soluble 
dexamethasone, adsorbed TGF-β1 and adsorbed dexamethasone, or tethered TGF-β1 
with soluble dexamethasone. In contrast to IGF-1, adsorbed TGF-β1 was able to 
stimulate BMSC sGAG production significantly higher than no TGF-β1 at all timepoints. 
By day 21, adsorbed TGF-β1 stimulated 31% as much sGAG as soluble TGF-β1 (Fig 
2.4A). Tethering TGF-β1 at up to 500 ng/mL did not stimulate sGAG production by 
BMSCs, similar to results seen with chondrocytes exposed to tethered IGF-1. In addition, 
tethering at 500 ng/mL significantly inhibited DNA accumulation compared to TGF-β1-
free gels at days 14 and 21 (Fig 2.4B). Soluble TGF-β1 stimulated an increase in DNA 
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over TGF-β1-free gels by day 21; adsorbed gels were not different from TGF-β1-free 
gels at any timepoint (Fig 2.4B).  
 
2.4 Discussion 
The optimal strategy for delivering growth factors to cells for the purposes of cartilage 
tissue engineering and cartilage repair remains an unmet challenge. Self-assembling 
peptides are a clinically relevant material that can be injected in vivo7, 8 and assemble on 
contact with solutions of physiologic pH and ionic strength49. We explored the ability of 
the self-assembling peptide hydrogel KLD to deliver IGF-1 and TGF-β1 to cells through 
two methods, tethering and adsorption of the growth factors to the peptide. While these 
growth factors can be tethered to KLD, they do not promote the same stimulation of 
matrix accumulation by chondrocytes or BMSCs compared to soluble delivery of these 
factors. In addition, both IGF-1 and TGF-β1 are able to be adsorbed to KLD, but only 
TGF-β1 is retained at sufficient quantity and duration to promote proteoglycan 
production. 
 
Although biotin-streptavidin tethering was shown by Davis et al. to be effective in 
delivering IGF-1 in order to reduce apoptosis of implanted cardiomyocytes8, it was not 
effective in delivering IGF-1 or TGF-β1 to stimulate proteoglycan production by 
chondrocytes or BMSCs, respectively, in the context of cartilage tissue engineering. Due 
to the strength of the non-covalent biotin-streptavidin bond (KD = 4x10-14 M)16 it is 
unlikely that the growth factors are released by this tether. Instead, the loss of bIGF-1 by 
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day 8 shown in Fig 1 is probably due to the degradation of the gel resulting in loss of the 
bKLD fibers to which the growth factors are attached. A difference in peptide gel 
degradation rates caused by differences in sequence, (RADA)4 vs. (KLDL)3, and by 
differences in cell type could therefore partly explain the differences between this study 
and that of Davis et al.8. Cartilage tissue also differs from myocardial tissue in that large 
amounts of extracellular matrix are produced, as early as one day after encapsulation. 
This matrix synthesis and secretion may prevent the stimulation of chondrocytes and 
BMSCs by immobilized factors by sterically blocking receptor-ligand binding. In 
addition, high-affinity tethering could block internalization of the ligand-receptor 
complex, which could limit bioactivity. Internalization of receptors is not required for 
TGF-β1 Smad2 signaling31, while IGF-1 signaling is thought to involve both cell surface 
and endosomal signaling4. However, inhibition of internalization may lead to altered 
signaling, resulting in lack of proteoglycan stimulation. Finally, while the density of 
tethered growth factors may also affect bioactivity42, both IGF-1 and TGF-β receptors 
exist as functional complexes on cell surfaces, and binding of one ligand can initiate 
signaling10, 41. Therefore, the distance between these immobilized growth factors should 
not have inhibited their effectiveness. Increasing the seeding density of chondrocytes 
(data not shown) or increasing the amount of growth factors immobilized within the 
scaffold had no effect. 
 
Growth factors, including TGF-β1, have been covalently immobilized or tethered onto 
other polymer scaffolds or hydrogels1, 9, 21, 22, 29, 35, although sometimes with altered 
signaling11, 36, 40. There have been a limited number of other attempts at delivering 
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tethered growth factors for the purposes of cartilage tissue engineering37. A possible 
solution to increase bioactivity of our tethering may be to include cleavable links in our 
peptide sequence. Lutolf et al. have proposed using MMP-cleavable links to deliver 
growth factors in poly(ethylene glycol)-based hydrogels upon catabolic events32, 33. In 
addition, Segers et al. directly inserted the protein SDF-1 onto the RAD peptide sequence 
with an MMP-cleavable linkage39. This idea may be adapted to our system by including 
such sequences appended to bKLD so that upon MMP cleavage, the growth factor 
complexes would become soluble. Other sequences may be more applicable for 
chondrogenic purposes, including sequences cleavable by the aggrecanases, ADMATS-
4/5. Finally, using tethers with a lower binding affinity may allow this method to result in 
better biological activity. 
 
Other methods for slow release of IGF-1 and TGF-β1 have been developed (see 28, 45 for 
review), but IGF-1 remains difficult to effectively deliver in vivo due to its small size and 
rapid diffusion out of tissue. A new fusion protein made by adding the heparin-binding 
domain of heparin-binding EGF to IGF-1 (i.e. HB-IGF-1) has been found to be amenable 
to delivery in mature articular cartilage46. A single dose of HB-IGF-1 resulted in 
sustained delivery and stimulation of proteoglycan synthesis for at least 8 days. The use 
of HB-IGF-1 with the KLD peptide system could be enabled by mixing in heparin, 
heparan sulfate, or the heparan sulfate proteoglycan, perlecan, with KLD. This approach 
has been shown to be effective in delivering other heparin-binding growth factors such as 
FGF-2 and BMP-2 to cells within fibrin19, collagen type 148, and PLGA20 scaffolds. 
Although adsorption of TGF-β1 to KLD effectively increased proteoglycan production in 
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our study, changing the degradation rates of KLD by changing the concentration or 
adding cross-links may offer a way of improving delivery.  
 
This study provided an initial evaluation of methods for delivering growth factors to cells 
within the self-assembling peptide hydrogel KLD, and showed that while TGF-β1 is able 
to be delivered by adsorption, IGF-1 is not. Additionally, while tethering these factors 
through a biotin-streptavidin bond provided long-term sequestration, tethered growth 
factors were not effective in stimulating proteoglycan production. Therefore, while 
peptide sequences are readily functionalized, the manner in which growth factors are 
delivered affects bioactivity and varies for specific growth factors and biological systems 
of interest. 
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2.7 Figures 
 
Figure 2.1. High-affinity tethering prolongs retention of IGF-1: Fluorescently labeled 
streptavidin and biotinylated-IGF-1 were either adsorbed or tethered to KLD prior to 
encapsulation of chondrocytes at 3x106 cells/mL. Background from the peptide was 
measured on gels without fluorescent streptavidin and subtracted from fluorescence 
counts. (A) Streptavidin retained immediately after gel assembly. (B) Streptavidin 
retained after 1, 4, or 8 days of culture. * vs. corresponding concentration adsorbed gel, 
p<0.05. mean ± SEM. (C) Fluorescence microscopy on gels at day 8 on gels without 
bIGF-1/fluorescent streptavidin, gels with 1000 ng/mL adsorbed bIGF-1/fluorescent 
streptavidin, or gels with 1000 ng/mL tethered bIGF-1/fluorescent streptavidin. Scale bar 
= 250 µm. 
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Figure 2.2. bIGF-1 is bioactive: Chondrocytes were encapsulated in KLD at 12x106 
cells/mL and cultured in medium with different soluble factors for four days. (A) sGAG 
and (B) DNA retained after culture in medium with soluble IGF-1 or soluble bIGF-1. (C) 
sGAG and (D) DNA retained after culture in medium with soluble bIGF-1 or soluble 
bIGF-1 + soluble streptavidin. mean ± SEM, * vs. No IGF, p<0.05. 
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Figure 2.3. Soluble IGF-1, but not adsorbed or tethered IGF-1, stimulates sGAG 
production: Biotinylated IGF-1 and streptavidin were either adsorbed or tethered to KLD 
at the indicated concentrations prior to encapsulation of chondrocytes at 3x106 cells/mL. 
No IGF-1 control gels were cultured in IGF-1-free medium. (A) sGAG and (B) DNA 
retained in gel. mean ± SEM, * vs. No IGF, p<0.05. 
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Figure 2.4. Soluble and adsorbed TGF-β1, but not tethered, promotes sGAG production: 
TGF-β1 and dexamethasone were adsorbed to KLD prior to assembly or biotinylated 
TGF-β1 and streptavidin were tethered to KLD prior to encapsulation of BMSCs at 3x106 
cells/mL. No TGF control gels were cultured in TGF-β1-free medium. Soluble 
dexamethasone (100 nM) was included in the medium for all conditions but adsorbed. 
(A) sGAG and (B) DNA retained in gel. mean ± SEM, * vs. No TGF, p<0.05. 
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Chapter 3. Effect of Self-assembling Peptide, Chondrogenic 
Factors, and Bone-Marrow-Derived Stromal Cells on 
Osteochondral Repair 
 
The goal of this study was to test the ability of an injectable self-assembling peptide 
(KLD) hydrogel with or without chondrogenic factors (CF) and allogeneic bone marrow 
stromal cells (BMSCs) to stimulate cartilage regeneration in a full-thickness, critically 
sized, rabbit cartilage defect model in vivo. We used CF treatments to test the hypotheses 
that CF would stimulate chondrogenesis and matrix production by cells migrating into 
acellular KLD (KLD+CF) or by BMSCs delivered in KLD (KLD+CF+BMSCs). Three 
groups were tested against contralateral untreated controls: KLD, KLD+CF, and 
KLD+CF+BMSCs, n=6-7. TGF-β1, dexamethasone, and IGF-1 were used as 
chondrogenic factors (CF) pre-mixed with KLD and BMSCs before injection. 
Evaluations included gross, histological, immunohistochemical and radiographic analyses. 
KLD without CF or BMSCs showed the greatest repair after 12 weeks with significantly 
higher Safranin-O, collagen II immunostaining, and cumulative histology scores than 
untreated contralateral controls. KLD+CF resulted in significantly higher aggrecan 
immunostaining than untreated contralateral controls. Including allogeneic BMSCs+CF 
markedly reduced the quality of repair and increased osteophyte formation compared to 
KLD alone. These data show that KLD can fill full-thickness osteochondral defects in 
situ and improve cartilage repair as shown by Safranin-O, collagen II immunostaining, 
and cumulative histology. In this small animal model, the full-thickness critically sized 
defect provided access to the marrow, similar in concept to abrasion arthroplasty or 
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spongialization in large animal models, and suggests that combining KLD with these 
techniques may improve current practice.  
 
3.1 Introduction  
Repair of articular cartilage injuries remains a challenge, despite the development of 
surgical treatments such as microfracture, abrasion arthroplasty, and spongialization, 
which are used with the goal of recruiting marrow-derived cells by penetration of the 
subchondral bone. While these techniques promote increased short-term healing, long-
term repair still consists of mechanically inferior fibrocartilage13. Recent research has 
focused on tissue engineering strategies using scaffolds to improve cartilage repair and 
regeneration. In particular, hydrogels made from materials such as chitosan-glycerol 
phosphate16, polyethyleneglycol (PEG)44, fibrin36, polyglycolic-co-lactic acid (PLGA)46, 
and collagen11 have been explored with the goal of improving the accumulation of 
extracellular matrix produced by cells (e.g., bone marrow stromal cells (BMSCs)) 
migrating into the scaffold from marrow.  
 
Stimulation of BMSC chondrogenesis in vitro and in vivo has received much attention. In 
vitro studies have shown that transforming growth factor-β1 (TGF-β1), dexamethasone, 
and insulin-like growth factor-1 (IGF-1) promote chondrogenesis of BMSCs22, 24, 25, 31, 49, 
and methods for delivering these chondrogenic factors have been developed, often in 
conjunction with scaffolds5, 17, 23, 38. There have been a number of in vivo studies 
performed delivering IGF-136, 40, TGF-β12, 13, 32, or the combination of IGF-1 and TGF-
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β117, 19, 40 to cartilage defects in order to stimulate chondrogenesis of endogenous 
BMSCs, but to our knowledge, no in vivo studies have incorporated dexamethasone.  
 
The hypothesis that delivery of exogenous BMSCs to the joint can enhance cartilage 
regeneration has prompted the exploration of a wide variety of growth factor and scaffold 
combinations to stimulate BMSC chondrogenesis13, 20, 37. In vivo studies have attempted 
to deliver BMSCs alone12, 35, BMSCs encapsulated in scaffolds30, 43, 48, and BMSCs 
encapsulated in scaffolds with the inclusion of TGF-β14, 7, 14, 15. Despite the in vitro 
promise shown by 3D-cultured BMSCs, most long-term in vivo treatments with BMSCs 
have resulted in sub-optimal cartilage repair tissue12, 20, 43, 48. Improving BMSC 
chondrogenesis in vivo is likely dependent on several factors that are not well understood, 
including cell delivery, microenvironment, and a combination of pro-chondrogenic 
longitudinal signaling. In addition, an ideal clinical approach would minimize or obviate 
the in vitro culture duration and be performed with a single arthroscopic procedure.  
 
Recent studies have shown that hydrogels made from the self-assembling peptide 
sequences (RADA)4 and (KLDL)3 (hereafter referred to as KLD) can maintain the 
chondrocyte phenotype26 and stimulate chondrogenesis of BMSCs in vitro6, 27, 29. These 
hydrogels have the ability to rapidly assemble when exposed to physiological pH and 
ionic strength50 and have pore sizes in the range of 100-500 nm42. These synthetic 
peptides have been used in vivo without immunogenic reaction3. Furthermore, TGF-β1 
has been shown to adsorb to KLD when pre-mixed with the peptide solution prior to 
assembly, resulting in extended delivery of TGF-β1 to BMSCs and stimulating 
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chondrogenesis in vitro, promoting sGAG production and accumulation comparable to 
continuous medium supplementation of TGF-β1 over 21 days28. In addition, including 
dexamethasone with TGF-β1 in medium supplementation during the in vitro culture of 
BMSCs in RADA results in less catabolic cleavage of aggrecan compared to culture with 
TGF-β1 alone8. Finally, IGF-1 can be tethered to peptide scaffolds via biotin-streptavidin 
bonds; this tethered IGF-1 has been shown to remain biologically active and to promote 
cell survival in rat cardiomyocytes over 28 days3. 
 
The goal of this study was to test the ability of an injectable KLD hydrogel with or 
without BMSCs and chondrogenic factors (CF) to stimulate cartilage regeneration in vivo 
in a critically sized rabbit full-thickness cartilage defect model. This model provides 
access to the marrow, analogous to abrasion arthroplasty or spongialization in large 
animal models. We used CF treatments (IGF-1, TGF-β1, and dexamethasone) to test the 
hypotheses that CF would stimulate chondrogenesis and matrix production (1) by cells 
migrating into acellular KLD and (2) by P2 passaged allogeneic BMSCs delivered in 
KLD. IGF-1 was tethered to the peptide with a biotin-streptavidin bond3 to stimulate 
long-term production of cartilage ECM, while TGF-β1 and dexamethasone were pre-
mixed with KLD prior to BMSC encapsulation to stimulate chondrogenesis and initial 
matrix production. A 12-week timepoint enabled evaluation of mid-term benefits of the 
treatment compared to contralateral untreated defects.  
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3.2 Materials and Methods  
Materials: KLD peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the 
MIT Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide 
synthesizer with FMOC protection. Human recombinant TGF-β1 (R&D Systems, Inc., 
Minneapolis, MN), dexamethasone (Sigma-Aldrich, St. Louis, MO), sucrose (Sigma-
Aldrich), biotinylated-IGF-1 (bIGF-1) (immunological and biochemical testsystems 
GmbH, Reutlingen Germany), streptavidin (Pierce Biotechnology, Inc, Rockford, IL), 
biotinylated-KLD (biotin-(aminocaproic acid)3-(KLDL)3 or b-KLD) (MIT Biopolymers 
Laboratory), FBS (Invitrogen, Carlsbad, CA), and FGF-2 (R&D Systems, Inc.) were 
purchased and used as described. 
 
Cell Isolation: Bone marrow was harvested and pooled from four rabbits used for an 
initial pilot study, and BMSCs were isolated as previously described29. BMSCs were 
selected via differential adhesion to plastic and expanded two passages in alphaMEM 
with 10% FBS and 2 ng/mL FGF-2, 10 mM HEPES, and PSA (100 U/mL penicillin, 100 
µg/mL streptomycin, and 250 ng/mL amphotericin), resulting in a total of approximately 
four population doublings. Each passage was conducted by seeding at a concentration of 
12x103 BMSCs/cm2 and incubating for two days to allow BMSCs to grow to ~75% 
confluence.  
 
In Vivo Study Design: All procedures were approved by the Animal Care and Use 
Committees at Colorado State University and Massachusetts Institute of Technology. 
Twenty skeletally mature, retired, female breeder New Zealand White rabbits (average 
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age 11 months and body weight 4.7 kg) were used for this study (Myrtle’s Rabbitry, 
Thompson Station, TN). One rabbit died during the study due to neurologic problems 
post-surgery and was not included in the analysis. The n values shown in Table 1 do not 
reflect this animal. Three different groups were tested against contralateral, untreated, 
empty controls: (1) KLD, (2) KLD+chondrogenic factors (CF), and (3) 
KLD+CF+BMSCs (Table 3.1). For all groups, KLD was resuspended in 10% sterile 
sucrose, and the final KLD concentration was kept constant at 3.2 mg/mL. For groups 2 
and 3, KLD peptide (48 µg) was pre-mixed with a CF mixture consisting of 1.4 ng TGF-
β1, 0.6 ng dexamethasone, 4.1 ng biotinylated-IGF-1 (bIGF-1), 30.7 ng streptavidin, and 
0.48 µg b-KLD. For group 3, 150x103 BMSCs were encapsulated in the KLD/CF 
mixture29. Encapsulation of BMSCs in vitro in this manner resulted in 80-90% viability. 
In vitro studies indicated that this amount of TGF-β1 would result in a concentration of 
TGF-β1 inside the scaffold sufficient to stimulate chondrogenesis28. At the same time, if 
all of the TGF-β1 were to be released from the scaffold at once into the joint space in vivo, 
it would amount to approximately 1 ng/mL concentration in the joint space (1.4 ng / 1.4 
mL joint space volume47), compared to the native concentration of 52.3 pg/mL found in 
adult rabbits47. Streptavidin and bIGF-1 were mixed at a 1:1 molar ratio in order to 
achieve, on average, binding of one bIGF-1 to each streptavidin allowing streptavidin to 
still bind b-KLD (in 100x molar excess of streptavidin and bIGF-1 to ensure 
homogeneous distribution of IGF-1 throughout the gel). The ability of this tethering to 
occur using these molar ratios has been shown in vitro and in vivo3. The amount of bIGF-
1 tethered was chosen to provide a local concentration of 300 ng/mL inside the scaffold, 
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which is above the threshold shown to be sufficient for chondrocyte stimulation of 
proteoglycan synthesis in vivo9.  
 
Defect Creation and Gel Injection: All surgical procedures were performed under 
inhalation general anesthesia. A medial-parapatellar arthrotomy approach to the 
femoropatellar joint was performed, and the patella was luxated laterally. A 3mm-diam x 
2mm-deep full-thickness, critically sized defect was created in the central region of the 
femoral trochlear groove (Fig 3.1). Direct pressure was applied with a surgical sponge to 
ensure all bleeding was stopped prior to application of the peptide, which was delivered 
as a liquid. Defects were filled with designated treatments (15 µL volume) or left 
untreated, as dictated by group assignment. The liquid peptide suspension could easily be 
seen filling the defect, and defects were filled until visually full. At this time, Lactated 
Ringer’s Solution was added to the joint periphery to gently fill the joint and cause 
polymerization of the peptide, which was visually inspected to ensure retention of the 
implant. Dorsal-caudal and lateral-medial 90º radiographs of each stifle joint were 
obtained immediately after surgery. At 12 weeks, rabbits were euthanized with 
pentobarbital after sedation. Post-surgical radiographic views were repeated following 
euthanasia.  
 
Gross Pathologic Observations of Joints: The limbs and joints were examined and 
graded by a blinded observer (DDF) unaware of treatment group (Table 3.2). For the 
muscle wastage measurement, the limbs were shaved and a flexible tape measure was 
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used in a similar anatomic location of the stifle to make this assessment. This scoring 
system was chosen in order to compare to other studies performed by Frisbie et al.11  
 
Synovial Membrane Histology: Synovial membrane was harvested and placed in 
neutral-buffered 10% formalin, embedded in paraffin, 5-µm sections created and stained 
with hematoxylin and eosin (H&E). Sections were evaluated blindly (DDF) for cellular 
infiltration, vascularity, intimal hyperplasia, subintimal edema and subintimal fibrosis on 
a scale of 0-4 (0=none, 1=slight, 2=mild, 3=moderate, 4=severe)10. 
 
Articular Cartilage Histology: Femoral sections for histology were fixed in neutral-
buffered 10% formalin, decalcified, embedded in paraffin, sectioned at 5 µm, and stained 
with either H&E or Safranin-O, fast green (SOFG) (ThermoScientific/Shandon VeriStain 
Gemini ES stainer) for proteoglycan visualization. Sections stained with H&E were 
evaluated blindly (DDF) using a modified O’Driscoll scoring system11, 39 (Table 3.3) with 
a maximum cumulative histology score of 28 and a higher score indicating a repair more 
like native cartilage. Sections stained with SOFG were evaluated blindly (DDF) for 
intensity of staining on a scale of 0-3 (Table 3.3) and were included in the cumulative 
histology score. 
 
Articular Cartilage Immunohistochemistry: For immunohistochemical analyses, 
femoral sections were snap frozen in OCT using liquid nitrogen and sectioned at 8 µm. 
Each section was incubated in 0.25 U/mL chondroitinase ABC (Sigma-Aldrich) for 15 
min before incubation in primary antibody solution (Collagen I (1:10) #M-38-s and II 
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(undiluted) # II-II6B3-s, Hybridoma Bank; Aggrecan (1:100, Alexis Biochemicals) 
#ALX-803-313; or rabbit IgG as control). Endogenous peroxidase was blocked using 
0.3% H2O2 in methanol. Sections were incubated in goat anti-mouse HRP secondary 
antibody solution (1:500, Jackson Immunoresearch, Westgrove, PA)), stained with 
Vector Nova RED (Vector Laboratories, Burlingame, CA) and counterstained with Fast 
Green. Controls gave no signal. Non-calcified tissues were evaluated blindly (DDF) for 
the percentage of repair tissue stained positive (0=no stain, 1=1-25%, 2=26-50%, 3=51-
75%, 4=76-100%). 
 
Radiographic Analysis: Radiographs and photographs were taken of bone segments 
from femoral sections. Radiographs were graded for presence of lysis, bony proliferation, 
osteophyte presence, and patellar luxation, and a total radiographic score was calculated 
by summing these scores (maximum score of 16). All grading was done on a 0-4 scale 
(0=none, 1=slight, 2=mild, 3=moderate, 4=severe)10, 12. Additionally, radiographs post-
euthanasia were scored for healing of the defect (0=no healing, 1=slight healing, 2=mild 
bone filling, 3=lesion is visible but difficult to measure, 4=lesion not visible to measure), 
sclerosis around the defect, and other sclerosis (0-4, none-severe). Sclerosis is defined as 
the increase in density of bone seen radiographically and was subjectively scored by 
MFB in a blinded fashion. 
 
Statistical Analyses: Scores were evaluated for inter- and intra-group differences using 
an ANOVA framework with PROC GLIMMIX (fits generalized linear mixed models) of 
SAS (Cary, NC)1 with rabbit as a random variable. For all joint pathologic, histological, 
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immunohistochemical, and radiographic analyses, intra-group differences were analyzed 
with treatment set as the main effect (one-way); differences among groups were analyzed 
using treatment and group as main effects (two-way). Untreated controls were therefore 
analyzed separately depending on what treatment the contralateral joint received in order 
to account for possible systemic effects18. When main or interaction effects had p-values 
that were considered significant (p-value < 0.05) or a trend (0.05 < p-value <0.10), 
individual comparisons were made using the least square means procedure12. P-values 
presented in the text include which main effect or interaction term they are referring to if 
quoted for comparisons among groups. All data are presented as mean ± standard error of 
the mean (SEM). Non-parametric analyses were also performed when appropriate. The 
authors were able to reach similar conclusions based on either analysis. Because the 
authors feel many of the biologic outcome parameters represent more of a continuum 
rather than defined categories, the parametric analysis of the data is presented.  
 
3.3 Results  
Radiographic Analyses: Radiographic analyses pre-treatment did not show any sclerosis 
in any of the rabbits. Treated defects post-treatment showed some slight osteophyte 
formation (0.333±0.139, treated; 0.056±0.143, untreated) (treatment p=0.087). There was 
no difference among groups (group p=0.490). 
 
Gross Observation of Joints: Upon necropsy, joints and incision areas in all 
experimental groups appeared normal by gross examination (Fig 3.1), and no 
inflammation or infection was noted, indicating no adverse immune reaction to the 
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treatments. Repair cartilage appeared to be moderately to normally attached to 
surrounding cartilage in all defects with no differences between treatments (treatment 
p=0.299) or groups (group p=0.541) (Table 3.4:XIII). Similarly, repair tissue ranged from 
normal to slightly soft compared to surrounding tissue when assessed for attachment to 
the subchondral bone, with no differences between treatments (treatment p=0.192) or 
groups (group p=0.970) (Table 3.4:XIV). Rabbits receiving KLD+CF+BMSCs (group 3) 
demonstrated mild osteophyte formation, with an increased score compared to KLD-
alone (group 1) (group p=0.029) (Fig 3.2A). Treated defects in group 3 also had better 
attachment to subchondral bone compared to untreated defects in group 3 (p=0.030) 
(Table 3.4:XIV). Overall, treated defects had an increased defect volume filled (treatment 
p= 0.032) and the level of treated defects was higher than contralateral untreated defects 
(treatment p=0.050) (Fig 3.1; Fig 3.2B,C). Untreated defects also had more muscle 
wastage at the site of incision (assessed by circumferential measurement at the proximal 
aspect of the patella), with group 1 and 3 treated defects different from their respective 
controls (treatment p=0.001, interaction p=0.032) (Fig 3.2D). Treated defects were scored 
higher in grade of repair compared to contralateral untreated defects, equivalent to a score 
of good (3.040±0.219, treated vs. 2.476±0.219, untreated, on a scale of 0-4) (treatment 
p=0.061).  
 
Histologic Examinations:  
Synovial Membrane H&E 
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Evaluation of the synovial membrane by H&E staining showed some mild intimal 
hyperplasia and some mild to moderate vascularity and subintimal fibrosis, but there 
were no differences among any groups or treatments.  
 
Articular Cartilage H&E 
Assessment of the articular cartilage H&E staining showed that KLD (group 1) had a 
higher cumulative histology score compared to contralateral untreated controls when 
looking at that group alone (p=0.034) (Fig 3.3A). When comparing among groups and 
treatments, KLD and KLD+CF (groups 1 and 2) had higher cumulative scores than 
KLD+CF+BMSCs (group 3) (group p=0.030) (Fig 3.3A). Defects treated with KLD 
received the highest score for nature of predominant tissue in the defect (see Table 3.3:I 
and Table 3.5:I), 1.00±0.276, or similar to fibrocartilage. The other groups and treatments 
ranged between 0 and 1, indicating presence of some fibrocartilage and some non-
chondrocytic cells; none of the groups or treatments were significantly different, however 
(group p=0.749, treatment p=0.264). Group 3 had significantly lower surface regularity 
(Table 3.3: II) with scores indicative of some fissuring of the surface (group p=0.005, Fig 
3.3B) and more degenerative change (Table 3.3: VIII) in cartilage surrounding the defect 
showing mild to moderate hypocellularity (group p=0.015) compared to KLD and 
KLD+CF (Fig 3.3C). Group 2 had more reconstitution of subchondral bone than group 3 
(group p=0.030), but all groups were still below normal subchondral bone levels (Fig 
3.3D; Table 3.3: IX). Group 2 also showed the highest score for bonding to adjacent 
cartilage (Table 3.5:V), but no groups or treatments were significantly different 
(treatment p=0.161, group p=0.226). Treated defects had increased cellularity (Table 
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3.3:VI) compared to contralateral untreated defects (treatment p=0.031) showing normal 
to slight hypocellularity in the treated defects repair tissue (1.778±0.110 vs. 
1.556±0.110); group 3 trended higher than the other groups (2.00±0.164, group 3; 
1.50±0.177, groups 1 and 2) (group p=0.081).  
 
Articular Cartilage SOFG: 
Defects treated with KLD-alone (group 1) had increased Safranin-O staining (scores of 
slight to moderate staining) than the contralateral untreated defects or treated defects in 
groups 2 and 3, which had only none to slight staining (interaction p=0.011) (Fig 3.4A). 
There was no overall effect of treatment or group on this measure (treatment p=0.286, 
group p=0.604). As shown in Fig 3.4B, treatment with KLD-alone resulted in greater 
staining throughout the repair tissue. 
 
Immunohistochemistry Evaluations: Looking at only group 1, defects treated with 
KLD showed increased collagen II immunostaining compared to contralateral untreated 
defects (p=0.028); although aggrecan immunostaining for defects treated with KLD 
received a score of 2.7, it was not different from the contralateral untreated control 
(p=0.526) (Fig 3.5A,B). This is in contrast to the difference observed in Safranin-O 
staining between defects treated with KLD and the contralateral untreated defects. In 
group 2, KLD+CF treatment elicited a tissue with higher aggrecan detected by 
immunostaining vs. the contralateral untreated control (p=0.041). In addition, although 
defects treated with KLD+CF received the highest collagen II immunostaining score of 
all the groups, 3.4, this was not different from its contralateral untreated control 
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(p=0.110). Comparing all defects, treated defects had more collagen II (treatment 
p=0.001) and increased aggrecan (treatment p=0.056) compared to untreated defects; 
there were no differences among groups (group p=0.293). There were similar levels of 
collagen I immunostaining found in all the defects (treatment p=0.471, group p=0.919), 
consistent with the observation of mostly fibrocartilage seen in the gross scoring (Fig 
3.5C). 
 
3.4 Discussion  
Treatment of full-thickness articular cartilage defects with the self-assembling peptide 
KLD (group 1) markedly improved cartilage regeneration, as seen by significant 
increases in cumulative histology score, Safranin-O staining, and collagen II 
immunostaining, compared to critically sized contralateral untreated defects. KLD has 
several advantages as a material due to its ability to be injected arthroscopically into a 
defect, assemble on contact with tissue, and promote cartilage regeneration without 
inducing an immune response. Adding TGF-β1, dexamethasone, and IGF-1 to KLD 
(group 2) resulted in increased aggrecan immunostaining, but in general did not result in 
any additional beneficial or deleterious effects compared to KLD alone. Motivated by in 
vitro results supporting BMSC chondrogenesis27-29, we delivered these factors with 
allogeneic BMSCs in KLD in vivo (group 3). However, this treatment resulted in a poorer 
repair than with KLD or KLD+CF. This is similar to other reports of fibrous tissue 
formation after BMSC treatment35, 43, 48, interpreted as a negative result.  
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In our rabbit model, the presence of a full-thickness defect allowed bone marrow to 
infiltrate the defect41 and act as a cell source, similar to abrasion arthroplasty and 
subchondral bone microfracture surgical techniques. The positive healing response seen 
with KLD treatment (group 1) demonstrates that the scaffold supports cell migration and 
further chondrogenesis of these cells in vivo. The high porosity of this scaffold (~99.6% 
water content26) is in agreement with a recent in vivo study in rabbits by Ikeda et al.21 
demonstrating that scaffolds with >85% porosity promoted migration of bone marrow 
cells into polymer scaffolds and with an in vitro study by Wang et al.45 demonstrating 
endothelial cell migration into several types of self-assembling hydrogels.   
 
Regarding group 2, KLD+CF treatment, our results raise the issues of whether the CF 
dose was appropriate to improve endogenous cell response and whether cells migrating 
into the scaffold in vivo respond differently to these CFs than in vitro and thereby require 
different stimulation. The inclusion of CFs did not show increased chondrogenesis over 
KLD alone (group 1) as determined by cumulative histology score, Safranin-O, aggrecan, 
and type II collagen immunostaining. Similar to these results, Holland et al.17 reported 
that TGF-β1 and IGF-1 delivered in gelatin microparticles within an acellular 
oligo(poly(ethylene glycol) fumarate) (OPF) scaffold resulted in repair no different than 
in empty defects, despite positive results in vitro. That study also delivered IGF-1 alone 
and found that this growth factor alone resulted in a significantly improved repair. In 
addition, other studies have looked at delivering IGF-1 alone in vivo and have reported 
similar positive results36, 40. While we did not test the effects of IGF-1 alone in this study, 
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our results emphasize the need for further understanding of the combination of IGF-1 
with other CF in vivo in order to take advantage of its characteristic anabolic properties.  
 
The intra-articular use of TGF-β1 remains controversial due to the pro-inflammatory 
response by the synovium seen at certain concentrations. Van der Kraan and van den 
Berg et al. have studied the interaction of TGF-β1 with various joint tissues and have 
shown that while TGF-β1 can stimulate proteoglycan production in cartilage, when it is 
exposed to synovial tissue, synovial fibrosis can occur; TGF-β1-induced osteophyte 
formation is also common2. Mi et al.32 showed that injection of recombinant adenoviral 
vector for hTGF-β1 into the knee joint space through the patellar tendon (resulting in 
~8.75 ng TGF-β1) dramatically increased joint inflammation, though this dose is more 
than 6-fold higher than our total dose of 1.4 ng. Accordingly, we did not observe these 
effects when TGF-β1 was added to the peptide alone (group 2). In contrast, when TGF-
β1 was added in combination with BMSCs (group 3), osteophyte formation increased, 
suggesting an interaction of TGF-β1 with these cells was responsible for the increased 
osteogenesis rather than the presence of TGF-β1 alone in the joint (group 2). This finding 
is similar to results recently published by Guo et al.15, in which 600 ng of TGF-β1 per mL 
of hydrogel was used in combination with BMSCs in an OPF scaffold. Furthermore, we 
observed a detrimental increase in osteophyte formation and distortion of normal joint 
anatomy when, in the same rabbit, 1.4 ng TGF-β1+BMSCs were placed in one joint and 
0.7 ng TGF-β1+BMSCs in the contralateral joint33. The authors were surprised at this 
result given the total body dose of TGF-β1 was only 1.5x what was used in group 2 or 
group 3 and the cell numbers 2-fold greater. While the amount of TGF-β1 delivered in 
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group 3 of our study was lower than that in the Mi32 study, and we attempted to deliver 
TGF-β1 in a controlled fashion, it is still possible that this TGF-β1 level was too high to 
beneficially induce chondrogenesis when combined with BMSCs, despite the inclusion of 
dexamethasone, which has been shown to enhance chondrogenesis compared to TGF-β1 
alone25, 34. A study by Fan et al. using only 0.8 ng of TGF-β1 with BMSCs in a gelatin-
chondroitin-hyaluronate tri-copolymer scaffold reported improved rabbit cartilage defect 
healing compared to treatment with BMSCs implanted in a scaffold without TGF-β1. 
Taken together, these studies suggest that while the amount of TGF-β1 we chose 
combined with BMSCs effectively induces chondrogenesis in vitro28, additional research 
is needed to determine a successful strategy for optimizing chondrogenesis of BMSCs in 
vivo, and interactions with synovial tissues must be considered.  
 
Due to the often noted ability of cartilage defects in young/skeletally immature rabbits to 
heal well naturally41, we used skeletally mature rabbits with average age of 11 months 
and critically sized defects in order to test the ability of treatment to improve adult animal 
healing. Although full-thickness defects were used, defects only entered the 
subchondral/trabecular bone, resulting in contralateral untreated defects that do not heal 
spontaneously by 12 weeks. These results are similar to other studies using similar-aged 
rabbits and defect sizes. A limitation of our model is the lack of enough tissue to perform 
direct biochemical assessment in addition to histological and immunohistochemical 
measurements in this study. However, the purpose of the present study was to perform an 
initial trial prior to a larger animal study where such additional measures will be utilized, 
since ample tissue will be available.  
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In summary, the self-assembling peptide hydrogel KLD offers a new material suitable for 
further testing in a clinically relevant defect in a large animal. We demonstrated 
improved filling of osteochondral defects and improved cartilage repair, as seen by 
cumulative histology score, Safranin-O staining, and type II collagen immunostaining. In 
this small animal model, the full-thickness defect provided access to the marrow, similar 
in concept to abrasion arthroplasty or spongialization in large animal models (goat, sheep, 
horse, human), and suggests that combining KLD with these techniques may offer an 
improvement over current practice. Ongoing studies include the evaluation of KLD in a 
clinically relevant sized equine defect co-treated with microfracture and subjected to 
strenuous exercise, compared to defects treated with microfracture alone.  
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3.7 Tables 
Table 3.1. Treatment groups with amounts delivered per animal. 
 
Group n KLD (µg) 
bKLD 
(µg) 
TGF-β1 
(ng) 
bIGF 
(ng) 
Streptavidin 
(ng) 
Dex 
(ng) 
BMSCs 
(x103) 
1 (KLD) 6 48 0.48 0 0 0 0 0 
2 (KLD+CF) 6 48 0.48 1.4 4.1 30.7 0.6 0 
3 (KLD+CF+BMSCs) 7 48 0.48 1.4 4.1 30.7 0.6 150 
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Table 3.2. Gross Observations Scoring System. 
Gross Observations Scoring System  
Feature               Score 
I. Joint Observation  
Normal appearance 0 
Slight inflammation 1 
Moderate inflammation 2 
Severe inflammation 3 
II. Incision Appearance  
Normal appearance 0 
Slight inflammation 1 
Moderate inflammation 2 
Severe inflammation 3 
Slight dehiscence (incision basically intact) 4 
Marked dehiscence (requires intervention) 5 
Active infection 6 
Healing infections 7 
III. Muscle wastage  
Circumferential measurement at the proximal aspect of the patella (cm) 
IV. Angle of Stifle: Change in normal angle (if any)  
None, within normal limits 0 
Abnormal 1 
V. Inflammation/Swelling  
None, within normal limits 0 
Abnormal 1 
VI. Trauma/Damage  
None, within normal limits 0 
Abnormal 1 
VII. Infection/Discharge  
None, within normal limits 0 
Abnormal 1 
VIII. Presence of Osteophytes and other Osteoarthritic 
Changes  
None, within normal limits 0 
Abnormal 1 
IX. Articular Surface Integrity, Contour, and Congruity  
Normal 0 
Abnormal 1 
X. Presence of Loose Bodies in Synovial Fluid  
None, within normal limits 0 
Abnormal 1 
XI. Injury to Apposing Articular Surface  
None, within normal limits 0 
Abnormal 1 
XII. Synovial Membrane Appearance                                                                 
Normal 0 
Slight 1 
Mild 2 
Moderate 3 
73 
Severe 4 
XIII. Cartilage Attachment 
This category describes on average the defect repair tissue 
attachment with the surrounding normal cartilage. Possible 
responses were:  
Normal Attachment 0 
Moderate Attachment 1 
Mild Attachment 2 
Slight Attachment 3 
No Attachment 4 
XIV. Bone Attachment 
This category describes the firmness of the repair tissue 
attachment to the bone at the base of the defect. Possible responses 
were:  
Similar to Surrounding Cartilage 0 
Slightly Soft-vs-Surrounding Cartilage 1 
Mildly Soft-vs-Surrounding Cartilage 2 
Moderately Soft-vs-Surrounding Cartilage 3 
Marked Softening-vs-Surrounding Cartilage 4 
XV. Firmness 
This category describes on average the firmness of the repair tissue 
to normal surrounding articular cartilage. Possible responses were:  
Similar Compared to Surrounding Cartilage 0 
Slightly Soft Compared to Surrounding Cartilage 1 
Mildly Soft Compared to Surrounding Cartilage 2 
Moderately Soft Compared to Surrounding Cartilage 3 
Marked Softening Compared to Surrounding Cartilage 4 
XVI. Blood 
This category describes the presence or absence of hemorrhage 
associated with the defect area or its periphery. Possible responses 
were:  
Fresh Blood, Active Hemorrage at Time of Surgery 1 
Old Blood, No Active Hemorrage at Time of Surgery 2 
No Blood Visualized at Time of Surgery 3 
XVII. Shape 
This category describes the margin of the defect as it relates to the 
original geometry at time 0 (creation). Possible responses were:  
No Apparent Change in Damage Tissue Beyond Defect 0 
Degeneration in Tissue Beyond Defect 1 
XVIII. Grade (Overall quality of repair) 
This category describes the overall subjective evaluation of the 
repair tissue by the evaluator. Criteria used to determine the grade 
were: 
(1) Attachment of repair tissue to the surrounding normal articular 
cartilage 
(2) Level (height) and undulation of the repair tissue surface as 
compared to the surrounding normal articular cartilage 
(3) Color of the repair tissue, where white homogenous tissue 
without a fibrous like appearance is used as the “gold standard.” 
Possible responses were:  
Tissue Not Present to Grade 0 
Poor 1 
Fair 2 
74 
Good 3 
Excellent 4 
XIX. Level  
This category describes the level of repair tissue filling in 
association with the surrounding normal articular cartilage. 
Possible responses in relation to the surrounding normal articular 
cartilage were:  
Mildly Recessed 1 
Slightly Recessed 2 
Leveled 3 
Slightly Elevated 4 
Mildly Elevated 5 
Moderately Elevated 6 
XX. Color 
This category describes the color of the repair tissue. When repair 
tissue is characterized by two colors, the predominate color is 
indicated first. Possible responses were:  
Red 1 
White/Red 2 
Yellow 3 
Yellow/White 4 
White/Yellow 5 
White 6 
XXI. Surface 
This category describes the relative undulation of the repair tissue 
surface. Possible responses were:  
Non-Undulating 1 
Slightly Undulating 2 
Mildly Undulating 3 
Moderatley Undulating 4 
XXII. Area  
Percent of Surface Area Filled in Defect (0-100%) 
XXIII. Volume  
Percent of Volume Filled in Defect (0-100%) 
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Table 3.3. Modified O’Driscoll Histological Scoring System 
Feature               Score 
I. Nature of the Repair Tissue  
Some Fibrocartilage, mostly nonchondrocytic cells                        0 
Mostly Fibrocartilage                    1 
Mixed Hyaline and Fibrocartilage   2 
Mostly Hyaline Cartilage 3 
Hyaline Cartilage                          4 
II. Surface Regularity  
Severe Disruption, Including Fibrillation                                                        0 
Fissures                                                                                                            1 
Superficial Horizontal Lamination                                                                  2 
Smooth and Intact                                                                                            3 
III. Structural Integrity (morphologic zone reconstitution)  
Severe Disintegration                                                                                      0 
Slight Disruption, Including Cysts                                                                  1 
Normal                                                                                                             2 
IV. Thickness  
0% - 50% of Normal Cartilage                                                                        0 
50% - 100% of Normal Cartilage                                                                    1 
100% of Normal Adjacent Cartilage                                                               2 
V. Bonding to Adjacent Cartilage  
Not Bonded                                                                                                     0 
Bonded at One End or Partially at Both Ends                                                 1 
Bonded at Both Ends of Graft                                                                         2 
VI. Hypocellularity  
Moderate Hypocellularity                                           0 
Slight Hypocellularity                                                                                     1 
Normal Cellularity                                                                                          2 
VII. Chondrocyte Clustering  
25% - 100% of the Cells                                                                                 0 
< 25% of the Cells                                                                                           1 
No Clusters                                                                                                      2 
VIII. Freedom from Degenerative Changes in Adjacent Cartilage  
Severe Hypocellularity, Poor or No Staining                                                 0 
Mild or Moderate Hypocellularity, Slight Staining                                        1 
Normal Cellularity, Mild Clusters, Moderate Staining                                  2 
Normal Cellularity, No Clusters, Normal Staining                                        3 
IX. Reconstitution of Subchondral Bone  
No Subchondral Bone Reconstitution                                                            0 
Minimal Subchondral Bone Reconstitution                                                    1 
Reduced Subchondral Bone Reconstitution                                                   2 
Normal                                                                                                           3 
X. Inflammatory Response in Subchondral Bone Region  
Severe                                                                                                             0 
Moderate                                                                                                       1 
None / Mild                                                                                                   2 
XI. Safranin-O Staining  
None                                                                                                              0 
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Slight                                                                                                              1 
Moderate                                                                                                        2 
Normal                                                                                                          3 
XII. Cumulative Histology Score (sum of above scores)                                                                                          0-28 
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Table 3.4. Gross Scores. One-way p-values for within group comparisons are listed in the 
untreated columns. Two-way p-values for differences among groups are in a separate 
column (TXT = treatment, Group = group, TXT*Group = interaction term). P-values are 
not shown when all the scores being compared are zero. 
 
Gross Scores KLD KLD+CF KLD+CF+BMSCs 
Feature               Treated untreated treated untreated treated untreated 
Two-way 
P-values 
I. Joint Observation 0±0 0±0 0±0 0±0 0±0 0±0  
II. Incision Appearance 0±0 0±0 0±0 0±0 0±0 0±0  
III. Muscle wastage 12.8±    0.3 
12.4±0.3, 
p=0.010 
12.8±    
0.3 
12.7±0.3, 
p=0.530 
13.0±    
0.3 
12.9±0.3, 
p=0.049 
TXT: 0.001 
Group:           
0.553 
TXT*Group:       
0.032 
IV. Angle of Stifle: 
Change in normal angle 
(if any) 
0±0 0±0 0±0 0±0 0±0 0±0  
V. Inflammation/ 
Swelling 0±0 0±0 0±0 0±0 0±0 0±0  
VI. Trauma/Damage 0±0 0±0 0±0 0±0 0±0 0±0  
VII. Infection/Discharge 0±0 0±0 0±0 0±0 0±0 0±0  
VIII. Osteophytes and 
other Osteoarthritic 
Changes 
0±0.2 0±0.2 0.2±0.2 0.2±0.2, 
p=1.000 
0.6±0.2 0.6±0.2, 
p=1.000 
TXT: 1.000 
Group: 0.029 
TXT*Group: 
1.000 
IX. Articular Surface 
Integrity, Contour, and 
Congruity 
0±0 0±0 0±0 0±0 0±0 0±0  
X. Presence of Loose 
Bodies in Synovial Fluid 0±0 0±0 0±0 0±0 0±0 0±0  
XI. Injury to Apposing 
Articular Surface 0±0 0±0 0±0 0±0 0±0 0±0  
XII. Synovial 
Membrane 0.5±0.2 
0.3±0.2, 
p=0.611 
0.2±0.2 0.3±0.2, 
p=0.562 
0.1±0.2 0.3±0.2, 
p=0.356 
TXT: 0.750 
Group: 0.685 
TXT*Group: 
0.605 
XIII. Cartilage 
Attachment to 
surrounding cartilage 
0.7±0.3 1.0±0.3, 
p=0.530 
0.5±0.3 0.3±0.3, 
p=0.611 
0.4±0.3 1.0±0.3, 
p=0.172 
TXT: 0.299 
Group: 0.541 
TXT*Group: 
0.423 
XIV. Bone Attachment 0.3±0.3 0.7±0.3, p=0.363 
0.7±0.3 0.5±0.3, 
p=0.695 
0.3±0.3 0.9±0.3, 
p=0.030 
TXT: 0.192 
Group: 0.970 
TXT*Group:    
0.262 
XV. Firmness 0.7±0.4 0.8±0.4, p=0.741 
1.0±0.4 0.5±0.4, 
p=0.296 
0.4±0.4 1.0±0.4, 
p=0.172 
TXT: 0.750 
Group: 0.995 
TXT*Group:   
0.222 
XVI. Blood 3.0±0.1 3.0±0.1, p=1.000 
3.0±0.1 3.0±0.1, 
p=1.000 
3.0±0.1 2.9±0.1, 
p=0.356 
TXT: 0.384 
Group: 0.450 
TXT*Group:    
0.450 
XVII. Shape 0±0 0±0 0±0 0±0 0±0 0±0  
XVIII. Grade (Overall 
quality of repair) 3.2±0.4 
2.2±0.4, 
p=0.076 
2.7±0.4 2.8±0.4, 
p=0.818 
3.3±0.4 2.4±0.4, 
p=0.017 
TXT: 0.061 
Group: 0.896 
TXT*Group:    
0.220 
XIX. Level 2.7±0.3 2.0±0.3, p=0.102 
2.5±0.3 2.3±0.3, 
p=0.695 
2.7±0.3 2.3±0.3, 
p=0.200 
TXT: 0.050 
Group: 0.897 
TXT*Group:   
0.613 
XX. Color 5.8±0.5 4.7±0.5, p=0.126 
4.8±0.5 4.8±0.5, 
p=1.000 
5.9±0.5 5.3±0.5, 
p=0.231 
TXT: 0.182 
Group: 0.363 
TXT*Group:    
0.547 
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XXI. Surface 1.8±0.3 2.2±0.3, p=0.465 
1.5±0.3 2.0±0.3, 
p=0.296 
1.7±0.3 2.0±0.3, 
p=0.457 
TXT: 0.127 
Group: 0.753 
TXT*Group:    
0.925 
XXII. Area 94.2±6.6 90.0±6.6, p=0.383 
95.7±6.6 90.0±6.6, 
p=0.441 
97.1±6.1 82.9±6.1, 
p=0.276 
TXT: 0.138 
Group:       
0.902 
TXT*Group:    
0.681 
XXIII. Volume 91.7±7.6 71.7±7.6, p=0.058 
88.2±7.6 80.8±7.6, 
p=0.477 
94.3±7.0 82.1±7.0, 
p=0.297 
TXT: 0.032 
Group:       
0.706 
TXT*Group:    
0.667 
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Table 3.5. Histological Scores. One-way p-values for within group comparisons are 
listed in the untreated columns. Two-way p-values for differences among groups are in a 
separate column. 
Histology Scores KLD KLD+CF KLD+CF+BMSCs 
Feature treated untreated treated untreated treated untreated 
Two-way 
p-values 
I. Nature of the 
Repair Tissue 1.0±0.3 
0.7±0.3, 
p=0.363 
0.7±0.3 0.7±0.3, 
p=1.000 
0.9±0.3 0.4±0.3, 
p=0.134 
TXT: 0.264 
Group:       
0.749 
TXT*Group:    
0.710 
II. Surface Regularity 2.5±0.3 2.2±0.3, p=0.175 
2.0±0.3 1.7±0.3, 
p=0.465 
1.4±0.3 0.9±0.3, 
p=0.298 
TXT: 0.130 
Group: 0.005 
TXT*Group:    
0.906 
III. Structural 
Integrity 1.3±0.2 1.0±0.2 1.2±0.2 
1.2±0.2, 
p=1.000 
0.9±0.2 0.7±0.2, 
p=0.563 
TXT: 0.284 
Group:       
0.118 
TXT*Group:    
0.655 
IV. Thickness 1.7±0.2 1.2±0.2, p=0.237 
1.5±0.2 1.7±0.2, 
p=0.611 
1.3±.2 1.3±0.2, 
p=1.000 
TXT: 0.583 
Group: 0.478 
TXT*Group:    
0.396 
V. Bonding to 
Adjacent Cartilage 0.7±0.3 
1.0±0.3, 
p=0.363 
1.3±0.3 1.3±0.3, 
p=1.000 
0.6±0.3 1.0±0.3, 
p=0.200 
TXT: 0.161 
Group:       
0.226 
TXT*Group:    
0.580 
VI. Hypocellularity 1.7±0.2 1.3±0.2, 
p=0.175 
1.7±0.2 1.3±0.2, 
p=0.175 
2.0±0.2 2.0±0.2, 
p=1.000 
TXT: 0.031 
Group: 0.081 
TXT*Group:    
0.259 
VII. Chondrocyte 
Clustering 1.7±0.2 
1.8±0.2, 
p=0.363 
1.7±0.2 1.7±0.2, 
p=1.000 
1.9±0.2 2.0±0.2, 
p=0.356 
TXT: 0.364 
Group:       
0.397 
TXT*Group:    
0.809 
VIII. Freedom from 
Degenerative 
Changes in Adjacent 
Cartilage 
1.7±0.2 1.8±0.2, 
p=0.611 
1.8±0.2 2.2±0.2, 
p=0.363 
1.3±0.2 1.0±0.2, 
p=0.172 
TXT: 0.658 
Group:       
0.015 
TXT*Group:    
0.270 
IX. Reconstitution of 
Subchondral Bone 1.8±0.3 
1.5±0.3, 
p=0.363 
2.2±0.3 2.0±0.3, 
p=0.695 
1.6±0.3 0.9±0.3, 
p=0.074 
TXT: 0.074 
Group:       
0.030 
TXT*Group:    
0.556 
X. Inflammatory 
Response in 
Subchondral Bone 
Region 
2.0±0.1 1.8±0.1, 
p=0.363 
2.0±0.1 2.0±0.1, 
p=1.000 
2.0±0.1 2.0±0.1, 
p=1.000 
TXT: 0.306 
Group:       
0.358 
TXT*Group:    
0.358 
XI. Safranin-O 
Staining 1.2±0.2 
0.2±0.2, 
p=0.012 
0.3±0.2 0.5±0.2, 
p=0.611 
0.3±0.2 0.6±0.2, 
p=0.337 
TXT: 0.286 
Group:       
0.604 
TXT*Group:    
0.011 
XII. Cumulative 
Histology Score (sum 
of above scores) 
17.2±1.1 14.5±1.1, 
p=0.034 
16.3±1.1 16.2±1.1, 
p=0.915 
14.0±1.0 12.7±1.0, 
p=0.417 
TXT: 0.140 
Group:       
0.030 
TXT*Group:    
0.541 
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3.8 Figures 
 
 
Figure 3.1. Gross necropsy photographs of treated and untreated joints in KLD, 
KLD+CF, and KLD+CF+BMSCs. 
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Figure 3.2. Gross pathologic observation of joints comparing KLD, KLD+CF, and 
KLD+CF+BMSCs treated and contralateral untreated defects. ; * p<0.05, † p=0.0292. 
(A) Gross osteophytes (scored as 0-1, where 0 = normal, 1 = abnormal); (B) Volume % 
Filled (scored as 0-100%); (C) Level of treated defects (scored as 1-6, where <3 is 
recessed, 3 is level with surrounding cartilage, and >3 is elevated); (D) Muscle wastage 
(circumference proximal to patella). 
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Figure 3.3. Histological scores comparing KLD, KLD+CF, and KLD+CF+BMSCs 
treated and untreated defects. Higher scores indicate more similar to native cartilage. (A) 
Cumulative histology (scored as 0-28); (B) Surface regularity (scored as 0-3); (C) 
Freedom from degenerative change of cartilage surrounding defect (scored as 0-3); (D) 
Reconstitution of subchondral bone (scored as 0-3); * p<0.05.  
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Figure 3.4. Safranin-O staining. (A) Scored as 0-3; * p<0.05. (B) Images showing 
histological evaluation of representative treatment groups and representative contralateral 
control knees. Treatment and contralateral pictures were representative of the mean 
scores and were taken from different animals for KLD and KLD+CF+BMSCs, and from 
the same animal for KLD+CF. Scale bar = 1 mm. 
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Figure 3.5. Immunohistochemistry scores (0-4). A) Aggrecan. B) Collagen II.               
C) Collagen I. * p<0.05. 
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Chapter 4. Intra-articular Injection of HB-IGF-1 Sustains 
Delivery of IGF-1 to Cartilage through Binding to Chondroitin 
Sulfate 
 
IGF-1 stimulates cartilage repair but is not a practical therapy due to its short half-life. 
We have previously modified IGF-1 by adding a heparin-binding domain and have 
shown that this fusion protein (HB-IGF-1) stimulates sustained proteoglycan synthesis in 
cartilage. Here, we first examined the mechanism by which HB-IGF-1 is retained in 
cartilage. We then tested whether HB-IGF-1 provides sustained growth factor delivery to 
cartilage in vivo and to human cartilage explants. Retention of HB-IGF-1 and IGF-1 was 
analyzed by Western blotting. The requirement of heparan sulfate (HS) or chondroitin 
sulfate (CS) glycosaminoglycans for binding was tested using enzymatic removal and 
cells with genetic deficiency of HS. Binding affinities of HB-IGF-1 and IGF-1 proteins 
for isolated glycosaminoglycans were examined by surface plasmon resonance and 
ELISA. In cartilage explants, chondroitinase treatment decreased binding of HB-IGF-1, 
whereas heparitinase had no effect. Furthermore, HS was not necessary for HB-IGF-1 
retention on cell monolayers. Binding assays showed that HB-IGF-1 bound both CS and 
HS, whereas IGF-1 did not bind either. After intra-articular injection in rat knees, HB-
IGF-1 was retained in articular and meniscal cartilages, but not in tendon, consistent with 
enhanced delivery to CS-rich cartilage. Finally, HB-IGF-1 but not IGF-1 was retained in 
human cartilage explants. After intra-articular injection in rats, HB-IGF-1 is specifically 
retained in cartilage through its high abundance of CS. Modification of growth factors 
with heparin-binding domains may be a new strategy for sustained and specific local 
delivery to cartilage. 
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4.1 Introduction 
Insulin-like growth factor-I (IGF-1) is known to be an important anabolic factor in 
cartilage homeostasis14. IGF-1 not only promotes synthesis of aggrecan, link protein, and 
hyaluronan3, 6, 34, it also inhibits proteoglycan degradation19, 29, 47. IGF-1 is primarily 
produced by the liver and reaches cartilage through the synovial fluid33, 42, 43, acting on 
chondrocytes through both autocrine and paracrine mechanisms27, 36. In multiple animal 
models of cartilage injury, viral delivery of IGF-1 has been successfully used to enhance 
cartilage repair15, 30.  
 
While IGF-1 may therefore be a potential therapeutic for cartilage repair, a clinically 
useful technique for non-viral IGF-1 delivery to cartilage has yet to be developed. A 
successful IGF-1 delivery strategy must overcome two major obstacles. First, IGF-1 has a 
short half-life of 8-16 hours in vivo when delivered systemically23. Second, systemic 
delivery of IGF-1 must be minimized since long-term excess circulating IGF-1 has been 
linked to increased risk for cancer5 and high-dose systemic IGF-1 administration causes 
significant adverse events21. Studies delivering IGF-1 directly to the joint through fibrin 
constructs11, 20, 37 have been promising, but rapid clearance of IGF-1 from the joint has 
prevented intra-articular injections of IGF-1 without a carrier from being effective42, and 
has been a limiting factor in delivery methods proposed to date.  
 
We have focused on the family of heparin-binding growth factors as a model for 
sequestration and sustained local delivery of growth factors to cartilage. Basic fibroblast 
growth factor (bFGF or FGF-2), vascular endothelial growth factor (VEGF), heparin-
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binding epidermal growth factor-like growth factor (HB-EGF), pleiotrophin, midkine, 
and platelet-derived growth factor (PDGF) are all members of the heparin-binding 
growth factor family and have been extensively studied for their ability to be retained in 
the extracellular matrix (ECM) of various tissues through their highly positively charged 
heparin-binding domains9, 22. Heparin-binding domains may be particularly relevant for 
localizing growth factors in cartilage. In particular, FGF-2 has been shown to bind to 
isolated highly negatively charged small leucine rich proteoglycan fibromodulin18 and to 
the heparan sulfate proteoglycan perlecan17, 50 in cartilage. Binding to ECM maintains a 
reservoir of FGF-2 that is released from the tissue upon cartilage injury or degradation18, 
48, 49, and binding to perlecan has been shown to protect FGF-2 from proteolytic 
degradation10, 41.  
 
Motivated by these considerations, we have designed a new strategy for local delivery of 
IGF-1 in various tissues:  we added the heparin-binding domain of HB-EGF to the 
amino-terminus of IGF-1 to create a new heparin-binding IGF-1 fusion protein, HB-IGF-
146. We have previously shown that HB-IGF-1 produces long-term delivery of 
bioavailable IGF-1 to bovine cartilage explants and a single dose stimulates a sustained 
increase in proteoglycan synthesis compared to IGF-1. However, the mechanism by 
which HB-IGF-1 is retained in tissues is not yet clear. Heparin-binding domains are all 
highly positively charged but the rigidity of their secondary structure varies, leading to 
different specificities for binding to heparan sulfate as opposed to other negatively 
charged sulfated glycosaminoglycans4, 45. Cartilage extracellular matrix (ECM) contains 
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primarily chondroitin sulfate (CS), while the pericellular matrix is rich in heparan sulfate 
(HS)9, 50. 
 
We hypothesized that HB-IGF-1 is retained in cartilage by binding heparan sulfate 
proteoglycans in the matrix and at the cell surface. In the present study, we tested this 
hypothesis by measuring release of bound HB-IGF-1 following chondroitinase or 
heparitinase treatment of cartilage explants, binding of HB-IGF-1 to cells unable to 
produce heparan sulfate, and the binding affinities of HB-IGF-1 for isolated heparan 
sulfate and chondroitin sulfate. Surprisingly, we found that HB-IGF-1 was retained 
primarily by binding to chondroitin sulfate, whereas heparan sulfate was not required. 
This result led us to test whether intra-articular injection of HB-IGF-1 allows sustained in 
vivo delivery preferentially to CS-rich rat knee cartilage and whether HB-IGF-1 can bind 
adult human cartilage. 
 
4.2 Materials and Methods 
Protein Production: HB-IGF-1 and IGF-1 were expressed in E. coli as Xpress and 
hexahistidine tagged proteins and were purified by Ni-NTA affinity followed by reverse-
phase chromatography, as previously described in detail46. 
 
Binding in Bovine Cartilage with GAG-ase Treatments: Cartilage disks (3 mm diameter, 
0.5 mm thick) from calf femoropatellar grooves were cultured in serum-free low glucose-
DMEM with 500 nM HB-IGF-1 or IGF-1 for 2 days. At Day 2, disks were washed with 
PBS and treated with either no enzyme, chondroitinase ABC (E.C. 4.2.2.4, Associates of 
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Cape Cod, Inc., East Falmouth, MA) (0.4 U/mL), or heparitinase (4:1 mixture of 
heparitinase I and II, E.C. 4.2.2.8, Associates of Cape Cod, Inc.) (0.036 U/mL). These 
enzymes have been shown to be specific for chondroitin sulfate38 and heparan sulfate44, 
respectively. At Day 4, half of the chondroitinase-treated disks were treated with 
heparitinase (0.036 U/mL); all other disks were incubated in enzyme-free medium (n=4). 
On Day 6, disks were flash frozen and protein was extracted by pulverization and by 
incubation with 100 mM NaCl, 50 mM Tris, 0.5% TritonX-100, pH 7.0 with protease 
inhibitor cocktail (Roche, Basel, Switzerland) rotating at 4 ˚C overnight. Protein was 
quantified by BCA assay (Thermo Fisher Scientific Inc., Rockford, IL) and equal 
amounts of protein were loaded on a 4-12% SDS-PAGE gel and analyzed by Western 
blot with anti-IGF-1 (1:500, Abcam Inc., Cambridge, MA, recognizes both HB-IGF-1 
and IGF-146). 5 ng of recombinant HB-IGF-1 was loaded as a protein standard and equal 
protein of an explant incubated with 500 nM IGF-1 for 2 days without enzyme treatment 
or washing was loaded as a positive control. HB-IGF-1 released to the medium was 
analyzed by ELISA as previously described46. Heparitinase activity was confirmed by 
assaying conditioned medium using an anti-HS-stub antibody 3G10 (1:500, Associates of 
Cape Cod, Inc.) by Western blot. This antibody has been shown previously to only detect 
neoepitopes generated by heparitinase cleavage and not by chondroitinase7. 
Chondroitinase activity was confirmed by assaying for GAG loss in treated explants 
using the DMMB dye binding assay, which showed that >75% sGAG was removed after 
48 h.  
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Binding to Chinese hamster ovary (CHO) cell surfaces: Mutant CHO cells unable to 
produce heparan sulfate (strain pgsD-677)26 and wildtype CHO (K1) cells were cultured 
in F12 medium supplemented with 10% FBS. At confluence, cells were washed with 
PBS and incubated in serum-free medium with 100 nM HB-IGF-1 or IGF-1. After 3 
hours, cells were washed 3x10 min with PBS and lysed with 50 mM Tris/HCl, 150 mM 
NaCl, 10 mM EDTA, 1% Triton X-100, 1% Igepal CA-630 (Sigma-Aldrich, St. Louis, 
MO), 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and protease 
inhibitor cocktail. Protein was quantified by BCA assay, and equal amounts of protein 
were analyzed by Western blot using anti-IGF-1 as described above. 5 ng of recombinant 
IGF-1 was loaded as a control. 
 
Biotinylation of Glycosaminoglycans (GAGs): Heparan sulfate (HS) (bovine kidney, 
Sigma, #H7640, 0.88 sulfates/disaccharide25) and chondroitin sulfate C (CS) (CS-C from 
shark cartilage, Sigma, #C4384, 0.99 sulfates/disaccharide25) (0.5 mg) were biotinylated 
mid-chain with Ez-Link-biotin hydrazide (Thermo Fisher Scientific Inc.) as previously 
described12 and purified following manufacturer instructions. Biotinylation was 
confirmed by dot blot using anti-biotin (1:500, Cell Signaling Technology, Danvers, MA).  
 
Binding Analysis via Surface Plasmon Resonance: All binding experiments were 
performed at room temperature at a flow rate of 20 µL/min on a Biacore2000 system (GE 
Healthcare, Buckinghamshire, UK). Biotinylated HS and CS were immobilized on 
separate flow cells of a streptavidin-coated Biacore chip (GE Healthcare, Piscataway, NJ) 
and coated with ~600 RU. Another flow cell was left untreated as a control. HB-IGF-1 or 
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IGF-1 was injected in running buffer consisting of 0.01M HEPES, 0.15M NaCl, 3mM 
EDTA, 0.005% Tween20, pH 7.4. KinInject was used to inject each IGF-1 over the chip 
with association and dissociation times of 5 min. The surface was regenerated by flowing 
1 M NaCl over the chip between experiments. Three to four concentrations of each IGF-1, 
with three repeats at each concentration, were performed for kinetic analyses. Control 
flow cell curves were subtracted from all binding curves in order to account for non-
specific binding and refractive index change. Association and dissociation rate constants 
(ka and kd respectively) were determined by fitting the measured binding curves globally 
with a 1:1 binding model using BIAevaluation software v4.1 and floating Rmax as a local 
parameter40. The equilibrium dissociation constant (KD) was calculated as kd/ka.  
 
ELISA Analysis of Binding to Biotinylated GAGs: Coating, blocking and washing buffers, 
secondary antibody, substrate, and stop solutions were purchased from KPL, Inc. 
(Gaithersburg, MD). Streptavidin-coated microplates (R&D Systems, Inc., Minneapolis, 
MN) were coated with biotinylated HS and CS at 20 µg/mL overnight at 4 ˚C. Plates 
were blocked for 15 min at room temperature before incubation with 0-500 nM HB-IGF-
1 or IGF-1 for one hour. Plates were washed three times and incubated with rabbit anti-
IGF-1 (10 µg/mL) (Abcam Inc.) for one hour at room temperature to detect protein bound 
to the biotinylated GAGs. After additional washes, anti-rabbit HRP (1:500) was applied 
for one hour at room temperature. Following final washes, color was developed by 
addition of ABTS peroxidase substrate solution. Absorbance was measured at 405 nm 
after quenching the wells with stop solution.  
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Rat Intra-articular Injection: 10 µg HB-IGF-1 in 50 µl saline, 10 µg IGF-1 in 50 µl saline, 
or 50 µl saline alone was injected into the right knee joint of 2-month-old male Sprague-
Dawley rats. After one day, joint tissues were harvested, extracted, and analyzed by 
Western blot. 5 ng of recombinant HB-IGF-1 or IGF-1 was loaded as standards. All 
animal procedures were approved by the Harvard Medical Area Standing Committee on 
Animals. 
 
Human Cartilage Binding Assay: Joints from 4 human subjects were obtained 
postmortem from the Gift of Hope Organ and Tissue Donor Network (Elmhurst, IL). 
Cartilage disks (3 mm diameter, 0.8 mm thick) were harvested from femoropatellar 
grooves of 26-year old (Collins grade 0)35, 49-year old (Collins grade 0), and 42-year old 
female (Collins grade 2) knee joints and from a 28-year old (Collins grade 0) male knee 
joint and cultured in 1% ITS serum-free high glucose DMEM supplemented with 500 nM 
HB-IGF-1 or IGF-1. After 48 h (Day 0), disks were washed with PBS and incubated in 
IGF-1 free medium. Disks were collected on Days 0, 1, 2 and 4, and protein was 
extracted and analyzed for IGF-1 bound by Western blot using anti-IGF-1. 5 ng of 
recombinant HB-IGF-1 or IGF-1 was loaded as standards. Procedures were approved by 
the Office of Research Affairs at Rush–Presbyterian–St. Luke’s Medical Center and the 
Committee on Use of Humans as Experimental Subjects at Massachusetts Institute of 
Technology. 
 
Statistical Analyses: All data are presented as mean ± standard error of the mean. Surface 
plasmon resonance binding constants were log-transformed and evaluated by Student’s t-
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test without assuming equal variances. Densitometry data for HB-IGF-1 binding to 
human cartilage were rank-transformed and evaluated by paired t-test. Densitometry data 
for HB-IGF-1 binding to CHO cells were rank-transformed and evaluated by Student’s t-
test without assuming equal variances. HB-IGF-1 loss to medium ELISA data were 
analyzed by one-way ANOVA. Immobilized GAG ELISA data were analyzed by two-
way ANOVA followed by Posthoc Tukey tests. All tests were performed with acceptance 
level α=0.05. 
 
4.3 Results 
HB-IGF-1 Is Retained in Cartilage Explants through Binding to Chondroitin Sulfate: To 
determine which GAG was more important for HB-IGF-1 retention in cartilage, we first 
tested whether removal of HS or CS affects HB-IGF-1 retention in cartilage explants. 
Explants were first incubated with 500 nM HB-IGF-1 or IGF-1 for 48 h (days 0-2, Fig 
4.1A). After washing the explants, they were then treated with either chondroitinase ABC, 
heparitinase, or no enzyme for another 48 h (days 2-4). To rule out the possibility that the 
high abundance of CS in the tissue could sterically block penetration of heparitinase into 
cartilage and therefore block heparitinase action, at day 4 half of the explants treated with 
chondroitinase were incubated with heparitinase for another two days. All other explants 
were incubated in medium with no added enzymes during this time (days 4-6). All 
explants were collected after this final incubation period (on day 6) and were analyzed by 
Western blot for HB-IGF-1 or IGF-1 remaining in the explant.  
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As shown previously46, cartilage explants incubated with IGF-1 in the medium for two 
days retained no IGF-1 in the tissue after 4 days of incubation in the absence of 
exogenous IGF-1 (Fig 4.1B). In contrast, in the absence of enzymatic treatment, HB-IGF-
1 was strongly retained in cartilage explants. Unexpectedly, treatment with heparitinase 
had no effect on the retention of HB-IGF-1 in the cartilage, whereas treatment with 
chondroitinase ABC caused a substantial decrease in HB-IGF-1 remaining in the tissue. 
While some HB-IGF-1 remained in the explants after treatment with chondroitinase, 
treatment of these explants with heparitinase did not reduce retention of HB-IGF-1 any 
further (Fig 4.1B, “C’ase+H’ase”). ELISA of conditioned medium confirmed that 
significantly more HB-IGF-1 was released from chondroitinase-treated cartilage than 
from heparitinase-treated cartilage, indicating comparatively low amounts of HB-IGF-1 
bound to heparan sulfate ex vivo (Fig 4.1C). 
 
Heparan Sulfate is Not Required for Retention of HB-IGF-1 on Cell Monolayers: To 
confirm that heparan sulfate is not required, we tested retention of HB-IGF-1 and IGF-1 
to mutant Chinese hamster ovary (CHO) cells (strain pgsD-677) that are unable to make 
HS due to a genetic defect in HS chain polymerization26. The mutant cells upregulate 
synthesis of CS and thus produce similar amounts of total sulfated GAG as the wild-type 
cells26. After incubation of CHO cells with 100 nM HB-IGF-1 or IGF-1 in serum-free 
medium, cells were washed and lysed for analysis by Western blot. HB-IGF-1 was 
retained in the wildtype CHO cells after washing, whereas no IGF-1 was retained (Fig 
4.2A,B). However, HB-IGF-1 was also retained in the HS-deficient cells, confirming that 
HB-IGF-1 can be retained by binding to CS in the absence of HS (Fig 4.2A,B). 
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HB-IGF-1 but not IGF-1 Binds Immobilized Glycosaminoglycans (GAGs): In order to 
quantify the binding affinities of HB-IGF-1 and IGF-1 for immobilized CS and HS, we 
used surface plasmon resonance. Comparable levels of biotinylated HS and CS were 
attached to a streptavidin-coated Biacore chip. A representative sensorgram is shown in 
Fig 4.3A, demonstrating that while IGF-1 does not bind to either GAG (response units 
(RU) <10), HB-IGF-1 binds to both HS and CS. Kinetic analysis of the surface plasmon 
resonance curves confirmed that although HB-IGF-1 bound HS significantly more 
strongly (KD = 21 ± 6 nM) than CS (KD = 160 ± 12 nM) (p = 0.012), the KD for the 
binding of HB-IGF-1 to CS is well within the range of reported receptor-ligand 
affinities24. This difference in KD values resulted from significantly different association 
rate constants, (ka = 16x104 ± 6.6x104 (1/M·s) for HS vs. ka = 1.5x104 ± 0.06x104 (1/M·s) 
for CS, p=0.035); the dissociation rates kd were similar (2.7x10-3 ± 0.93x10-3 (1/s) for HS 
vs. 2.5x10-3 ± 0.16x10-3 (1/s) for CS), p=0.85).  
 
The relative differences in binding affinities of HB-IGF-1 and IGF-1 to HS and CS were 
confirmed by a sandwich ELISA. Binding of HB-IGF-1 to immobilized HS and CS 
increased with concentration, with more binding to HS at the same given concentration of 
HS or CS contained in each well (Fig 4.3B). Therefore, although HB-IGF-1 binds HS 
with higher affinity, the data suggest that binding to CS would dominate in cartilage 
tissue, where CS is ~500-1000 more abundant than HS16, 50. 
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HB-IGF-1 Is Preferentially Retained in Cartilage after Intra-articular Injection: The 
ability of HB-IGF-1 to bind CS led us to hypothesize that it would be retained 
preferentially in the GAG-rich cartilage tissues if delivered by intra-articular injection. 
Consistent with this hypothesis, we found that one day after intra-articular injection in a 
rat knee, HB-IGF-1 remained strongly detectable in articular cartilage extracts (Fig 4.4, 
Articular Cartilage), despite stronger immunoreactivity of the IGF-1. HB-IGF-1 was also 
slightly detectable in extracts of the fibrocartilaginous meniscus (Fig 4.4, Meniscus). In 
contrast, HB-IGF-1 was not detectable in patella, patellar tendon, or muscle extracts (Fig 
4.4). IGF-1 was not detectable in any of the tissues one day after injection (Fig 4.4). 
 
HB-IGF-1 Is Retained in Human Cartilage: To examine whether HB-IGF-1 may be 
relevant as a strategy for clinical delivery of growth factors to cartilage, we tested 
whether HB-IGF-1 could also be retained in post-mortem adult human cartilage explants. 
Human knee cartilage obtained from three Collins grade 0 donor joints (both male and 
female) and one Collins grade 2 joint (female) was incubated with 500 nM HB-IGF-1 or 
IGF-1 for two days, washed with PBS, and incubated in no-IGF-1 medium for an 
additional 0, 1, 2, or 4 days. Binding of IGF-1 was only detectable immediately after 
washing out the IGF (Fig 4.5A, Day 0). In contrast, HB-IGF-1 was retained after further 
incubation for up to 4 days (Fig 4.5A). Analysis of Western blots from the four donor 
cartilages by densitometry demonstrated that retention of HB-IGF-1 was significantly 
higher than IGF-1 after 1, 2, and 4 days of incubation (Fig 4.5B). 
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4.4 Discussion 
We demonstrate here that adding a heparin-binding motif to IGF-1 converts it from a 
short-acting growth factor to one that can be locally delivered and retained in articular 
cartilage in vivo. Contrary to our initial expectations, HB-IGF-1 does not require heparan 
sulfate for retention in either cell culture or in cartilage explants. While we show that HB-
IGF-1 does have a higher affinity for heparan sulfate, its affinity for chondroitin sulfate is 
within an order of magnitude. Therefore, in cartilage, where CS concentrations are 500-
1000 times higher than HS16, 50, binding to CS dominates and retention of HB-IGF-1 is 
independent of HS. 
 
These results led us to hypothesize that HB-IGF-1 could be preferentially delivered and 
retained in articular cartilage due to its high concentration of sulfated 
glycosaminoglycans14. We tested this hypothesis in rats and showed that after intra-
articular injection, HB-IGF-1 remains bound to the CS-rich articular cartilage, but not to 
the adjacent patella, patellar tendon, or muscle tissue. In contrast, unmodified IGF-1 is 
not able to bind either CS or HS, and was not detectable in either tissue after intra-
articular injection. Finally, we demonstrated that HB-IGF-1 is retained in adult human 
cartilage whereas unmodified IGF-1 is not. Taken together, the results suggest that 
modification of growth factors with heparin-binding domains may be a clinically relevant 
strategy for local delivery to cartilage. 
 
Our finding that HB-IGF-1 is retained primarily by chondroitin sulfate contrasts with the 
extensive work demonstrating that the heparin-binding domain of FGF-2 binds primarily 
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to heparan sulfate proteoglycans in cartilage17, 50. This is likely explained by differences 
in the binding specificities of the heparin-binding domains. In general, specificity for HS 
depends on not only the heparin binding domains, but also on the secondary and/or 
tertiary structure of the native proteins. The heparin-binding domain we used here to 
make HB-IGF-1 came from HB-EGF. Structure-function analysis of HB-EGF has shown 
that in addition to the heparin-binding domain, a portion of the EGF-like domain45 is 
required for binding specifically to heparan sulfate. Similarly, FGF-2 affinity for HS has 
been shown to depend on the spatial distribution of basic amino acids within the heparin-
binding loops of this molecule and on the specific conformation and topological 
arrangement of these loops39. Since we added only the heparin-binding domain of HB-
EGF to IGF-1, it is likely that charge plays a primary role in the interactions of HB-IGF-1, 
allowing it to bind other negatively charged glycosaminoglycans such as CS. 
 
FGF-2 also appears to be retained in pericellular matrix as a reservoir of the growth 
factor that does not activate the chondrocytes until released by matrix mechanical 
stimulation or trauma.  While we have not shown specific binding locations within 
cartilage, we have previously demonstrated that retention of HB-IGF-1 is accompanied 
by a sustained increase in 35S-sulfate incorporation46, strongly suggesting that factors 
retained by chondroitin sulfate represent a pool that remains available to stimulate 
chondrocyte receptors at the cell surface.  
 
There may be additional mechanisms that are contributing to the differences seen here 
between HB-IGF-1 and un-modified IGF-1. In particular, previous work has shown that 
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IGF-1 binds primarily to IGF binding proteins (IGFBPs) in cartilage, and not to ECM 
constituents2, 13. Cartilage from osteoarthritic patients is known to be less responsive to 
IGF-114, in part due to increased levels of IGF binding proteins (IGFBPs)8, 14, 28, 31, 32. 
IGFBPs are present at a binding site density of 30-150 nM in bovine cartilage13 and can 
bind IGF-1 with an equilibrium affinity (KD) of ~5 nM13. The KD found for HB-IGF-1 
binding to heparan sulfate is on the order of that found for IGF-1 binding to IGFBPs, 
indicating that it may be able to compete for IGFBP binding, possibly resulting in more 
bioactivity than normal IGF-1 in addition to better delivery. Moreover, the modification 
of the amino-terminus of IGF-1 by inclusion of the heparin-binding domain may decrease 
the affinity of HB-IGF-1 to IGFBPs, as the deletion of the first three amino acids in the 
case of the mutated analog des(1-3)IGF-1 decreased binding to IGFBPs by 100-fold1.  
 
In conclusion, HB-IGF-1 may be a new therapeutic for sustained and relatively specific 
local delivery of IGF-1 to cartilage through its preferential retention in CS-rich tissues. 
Modification of growth factors by addition of heparin binding domains may therefore be 
a novel strategy for targeted delivery to cartilage after intra-articular injection. 
 
4.5 Acknowledgements 
I would like to thank Alan J. Grodzinsky, Sc.D., Richard T. Lee, M.D., and Parth Patwari, 
M.D., Sc.D. for their scientific guidance, Kiersten Cummings, B.S. for her expertise in 
manufacturing HB-IGF-1, and Anna H. K. Plaas, Ph.D. and Ada A. Cole, Ph.D. for 
supplying human donor tissue. I would also like to thank Dr. Jeff Esko for helpful 
discussions. Finally, I am grateful for the following funding sources: NIH-NIBIB Grant 
100 
EB003805 and NIH-NIAMS Grant AR045779; NDSEG and NSF graduate fellowships; a 
collaborative research grant from the Massachusetts Life Sciences Center and funding 
from Biomeasure, Inc. 
 
4.6 References 
1. Bagley CJ, May BL, Szabo L, McNamara PJ, Ross M, Francis GL, Ballard FJ, 
and Wallace JC. A key functional role for the insulin-like growth factor 1 N-
terminal pentapeptide. Biochem J. 1989; 259:665-71. 
2. Bhakta NR, Garcia AM, Frank EH, Grodzinsky AJ, and Morales TI. The Insulin-
like Growth Factors (IGFs) I and II Bind to Articular Cartilage via the IGF-
binding Proteins. J Biol Chem. 2000; 275:5860-5866. 
3. Bonassar LJ, Grodzinsky AJ, Frank EH, Davila SG, Bhaktav NR, and Trippel SB. 
The effect of dynamic compression on the response of articular cartilage to 
insulin-like growth factor-I. J Orthop Res. 2001; 19:11-17. 
4. Cardin AD and Weintraub HJ. Molecular modeling of protein-glycosaminoglycan 
interactions. Arterioscler Thromb Vasc Biol. 1989; 9:21-32. 
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens 
CH, and Pollak M. Plasma Insulin-Like Growth Factor-I and Prostate Cancer 
Risk: A Prospective Study. Science. 1998; 279:563-566. 
6. Curtis AJ, Devenish RJ, and Handley CJ. Modulation of aggrecan and link-
protein synthesis in articular cartilage. Biochem J. 1992; 288:721-726. 
7. David G, Bai XM, Van der Schueren B, Cassiman JJ, and Van den Berghe H. 
Developmental changes in heparan sulfate expression: in situ detection with 
mAbs. J. Cell Biol. 1992; 119:961-975. 
8. Dore S, Pelletier JP, DiBattista JA, Tardif G, Brazeau P, and Martel-Pelletier J. 
Human osteoarthritic chondrocytes possess an increased number of insulin-like 
growth factor 1 binding sites but are unresponsive to its stimulation. Possible role 
of IGF-1-binding proteins. Arthritis Rheum. 1994; 37:253-63. 
9. Farach-Carson MC, Hecht JT, and Carson DD. Heparan Sulfate Proteoglycans: 
Key Players in Cartilage Biology. Critical Reviews in Eukaryotic Gene 
Expression. 2005; 15:29-48. 
10. Flaumenhaft R, Moscatelli D, Saksela O, and Rifkin DB. Role of extracellular 
matrix in the action of basic fibroblast growth factor: Matrix as a source of growth 
factor for long-term stimulation of plasminogen activator production and DNA 
synthesis. J Cellular Physiology. 1989; 140:75-81. 
11. Fortier LA, Mohammed HO, Lust G, and Nixon AJ. Insulin-like growth factor-I 
enhances cell-based repair of articular cartilage. J Bone Joint Surg Br. 2002; 84-
B:276-288. 
12. Friedrich U, Blom AM, Dahlback B, and Villoutreix BO. Structural and Energetic 
Characteristics of the Heparin-binding Site in Antithrombotic Protein C. J. Biol. 
Chem. 2001; 276:24122-24128. 
101 
13. Garcia A, Szasz N, Trippel SB, Morales T, Grodzinsky AJ, and Frank E. 
Transport and binding of insulin-like growth factor I through articular cartilage. 
Arch Biochem Biophys. 2003; 415:69-79. 
14. Goldring MB. Update on the biology of the chondrocyte and new approaches to 
treating cartilage diseases. Best Practice & Research Clinical Rheumatology. 
2006; 20:1003-1025. 
15. Goodrich LR, Hidaka C, Robbins PD, Evans CH, and Nixon AJ. Genetic 
modification of chondrocytes with insulin-like growth factor-1 enhances cartilage 
healing in an equine model. J Bone Joint Surg Br. 2007; 89-B:672-685. 
16. Govindraj P, West L, Koob TJ, Neame P, Doege K, and Hassell JR. Isolation and 
Identification of the Major Heparan Sulfate Proteoglycans in the Developing 
Bovine Rib Growth Plate. J Biol Chem. 2002; 277:19461-19469. 
17. Govindraj P, West L, Smith S, and Hassell JR. Modulation of FGF-2 binding to 
chondrocytes from the developing growth plate by perlecan. Matrix Biol. 2006; 
25:232-9. 
18. Heinegard D. Proteoglycans and more - from molecules to biology. Int J Exp Path. 
2009; 90:575-586. 
19. Hui W, Rowan AD, and Cawston T. Modulation of the expression of matrix 
metalloproteinase and tissue inhibitors of metalloproteinases by TGF-β1 and IGF-
1 in primary human articular and bovine nasal chondrocytes stimulated with TNF-
α. Cytokine. 2001; 16:31-35. 
20. Hunziker EB and Rosenberg LC. Repair of partial-thickness defects in articular 
cartilage: cell recruitment from the synovial membrane. J Bone Joint Surg Am. 
1996; 78:721-33. 
21. Jabri N, Schalch D, Schwartz S, Fischer J, Kipnes M, Radnik B, Turman N, 
Marcsisin V, and Guler H. Adverse effects of recombinant human insulin-like 
growth factor I in obese insulin-resistant type II diabetic patients. Diabetes. 1994; 
43:369-374. 
22. Kirn-Safran CB, Gomes RR, Brown AJ, and Carson DD. Heparan sulfate 
proteoglycans: Coordinators of multiple signaling pathways during 
chondrogenesis. Birth Defects Research Part C: Embryo Today: Reviews. 2004; 
72:69-88. 
23. Laron Z. Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1): Clinical 
Pharmacology and Potential Treatment of Endocrine and Metabolic Disorders. 
BioDrugs. 1999; 11:55-70. 
24. Lauffenburger DA and Linderman JJ. Receptors: Models for Binding, Trafficking, 
and Signaling. 1993, New York: Oxford University Press. 
25. Ley K, Cerrito M, and Arfors K-E. Sulfated polysaccharides inhibit leukocyte 
rolling in rabbit mesentery venules. Am J Physiol. 1991; 260:H1667-H1673. 
26. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, Massague J, 
Lindahl U, and Esko JD. A single mutation affects both N-
acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese 
hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl 
Acad Sci U S A. 1992; 89:2267-2271. 
102 
27. Loeser RF and Shanker G. Autocrine stimulation by insulin-like growth factor 1 
and insulin-like growth factor 2 mediates chondrocyte survival in vitro. Arthritis 
Rheum. 2000; 43:1552-1559. 
28. Loeser RF, Shanker G, Carlson C, Gardin J, Shelton B, and Sonntag W. 
Reduction in the chondrocyte response to insulin-like growth factor in aging and 
osteoarthritis. Arthritis Rheum. 2000; 43:2110-2120. 
29. Luyten FP, Hascall VC, Nissley SP, Morales TI, and Reddi AH. Insulin-like 
growth factors maintain steady-state metabolism of proteoglycans in bovine 
articular cartilage explants. Arch Biochem Biophys. 1988; 267:416-425. 
30. Madry H, Kaul G, Cucchiarini M, Stein U, Zurakowski D, Remberger K, Menger 
MD, Kohn D, and Trippel SB. Enhanced repair of articular cartilage defects in 
vivo by transplanted chondrocytes overexpressing insulin-like growth factor I 
(IGF-I). Gene Ther. 2005; 12:1171-1179. 
31. Martel-Pelletier J, Di Battista JA, Lajeunesse D, and Pelletier JP. IGF/IGFBP axis 
in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res. 1998; 47:90-100. 
32. Martin JA, Ellerbroek SM, and Buckwalter JA. Age-related decline in 
chondrocyte response to insulin-like growth factor-I: The role of growth factor 
binding proteins. J Orthop Res. 1997; 15:491-498. 
33. Matsumoto T, Gargosky SE, Iwasaki K, and Rosenfeld RG. Identification and 
characterization of insulin-like growth factors (IGFs), IGF-binding proteins 
(IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol 
Metab. 1996; 81:150-5. 
34. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, Milway VE, and Herinton 
AC. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth 
factor-I in cultured bovine articular cartilage. Biochem J. 1986; 240:423-430. 
35. Muehleman C, Bareither D, Huch K, Cole AA, and Kuettner KE. Prevalence of 
degenerative morphological changes in the joints of the lower extremity. 
Osteoarthritis Cartilage. 1997; 5:23-37. 
36. Nixon A, Saxer R, and Brower-Toland BD. Exogenous insulin-like growth factor-
I stimulates an autoinductive IGF-I autocrine/paracrine response in chondrocytes. 
J Orthop Res. 2001; 19:26-32. 
37. Nixon AJ, Fortier LA, Williams J, and Mohammed H. Enhanced repair of 
extensive articular defects by insulin-like growth factor-I-laden fibrin composites. 
J Orthop Res. 1999; 17:475-87. 
38. Oike Y, Kimata K, Shinomura T, Nakazawa K, and Suzuki S. Structural analysis 
of chick-embryo cartilage proteoglycan by selective degradation with chondroitin 
lyases (chondroitinases) and endo-beta-D-galactosidase (keratanase). Biochem J. 
1980; 191:193-207. 
39. Raman R, Venkataraman G, Ernst S, Sasisekharan V, and Sasisekharan R. 
Structural specificity of heparin binding in the fibroblast growth factor family of 
proteins. Proc Natl Acad Sci U S A. 2003; 100:2357-62. 
40. Ricard-Blum S, Feraud O, Lortat-Jacob H, Rencurosi A, Fukai N, Dkhissi F, 
Vittet D, Imberty A, Olsen BR, and van der Rest M. Characterization of 
Endostatin Binding to Heparin and Heparan Sulfate by Surface Plasmon 
Resonance and Molecular Modeling. J Biol Chem. 2004; 279:2927-2936. 
103 
41. Saksela O, Moscatelli D, Sommer A, and Rifkin DB. Endothelial cell-derived 
heparan sulfate binds basic fibroblast growth factor and protects it from 
proteolytic degradation. J Cell Biol. 1988; 107:743-51. 
42. Schmidt MB, Chen EH, and Lynch SE. A review of the effects of insulin-like 
growth factor and platelet derived growth factor on in vivo cartilage healing and 
repair. Osteoarthritis Cartilage. 2006; 14:403-412. 
43. Schneiderman R, Rosenberg N, Hiss J, Lee P, Liu F, Hintz RL, and Maroudas A. 
Concentration and size distribution of insulin-like growth factor-1 in human 
normal and osteoarthritic synovial fluid and cartilage. Arch Biochem Biophys. 
1995; 324:173-188. 
44. Silverberg I, Havsmark B, and Fransson L-Å. The substrate specificity of heparan 
sulphate lyase and heparin lyase from Flavobacterium heparinum. Carbohydrate 
Research. 1985; 137:227-238. 
45. Thompson SA, Higashiyama S, Wood K, Pollitt NS, Damm D, McEnroe G, 
Garrick B, Ashton N, Lau K, Hancock N, Klagsbrun M, and Abraham JA. 
Characterization of sequences within heparin-binding EGF-like growth factor that 
mediates interaction with heparin. J Biol Chem. 1994; 269:2541-2549. 
46. Tokunou T, Miller R, Patwari P, Davis ME, Segers VF, Grodzinsky AJ, and Lee 
RT. Engineering insulin-like growth factor-1 for local delivery. FASEB J. 2008; 
22:1886-93. 
47. Tyler JA. Insulin-like growth factor I can decrease degradation and promote 
synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J. 1989; 
260:543-548. 
48. Vincent T, Hermansson M, Bolton M, Wait R, and Saklatvala J. Basic FGF 
mediates an immediate response of articular cartilage to mechanical injury. Proc 
Natl Acad Sci U S A. 2002; 99:8259-64. 
49. Vincent TL, Hermansson MA, Hansen UN, Amis AA, and Saklatvala J. Basic 
fibroblast growth factor mediates transduction of mechanical signals when 
articular cartilage is loaded. Arthritis Rheum. 2004; 50:526-33. 
50. Vincent TL, McLean CJ, Full LE, Peston D, and Saklatvala J. FGF-2 is bound to 
perlecan in the pericellular matrix of articular cartilage, where it acts as a 
chondrocyte mechanotransducer. Osteoarthritis Cartilage. 2007; 15:752-63. 
 
 
 
 
 
 
 
 
104 
4.7 Figures 
 
 
Figure 4.1. Retention of HB-IGF-1 in bovine cartilage explants following enzymatic 
digestion of glycosaminoglycans. (A) HB-IGF-1 (HB) or IGF-1 (I) was incubated with 
cartilage disks for two days (Day 0 to Day 2) followed by treatment with no enzyme (No 
Enz), chondroitinase (C’ase), or heparitinase (H’ase) for an additional two days (Day 2 to 
Day 4). At Day 4, a subset of chondroitinase-treated disks was incubated with 
heparitinase (C’ase+H’ase) for two days while all remaining disks were kept in enzyme-
free medium. (B) Western analysis of HB-IGF-1 or IGF-1 remaining in the cartilage 
tissue at Day 6. The blot shown is representative of four repeats. (C) ELISA of HB-IGF-1 
released to the medium following 48-hour enzyme treatment of cartilage explants (Days 
2-4 for No enzyme, C’ase, and H’ase conditions; Days 4-6 for C’ase + H’ase). mean ± 
SEM, * vs. No enzyme, n=4, p<0.001. 
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Figure 4.2. Retention of HB-IGF-1 on cells lacking heparan sulfate. (A) HB-IGF-1 
(“HB”) and IGF-1 (“I”) were incubated with mutant CHO cells unable to produce 
heparan sulfate (“no HS”) and wildtype CHO cells (“WT”), then washed in PBS. 
Western analysis of the cell lysates for IGF showed that HB-IGF-1 remained bound to 
cells with or without the presence of heparan sulfate, whereas IGF-1 binding was not 
detectable. (B) Densitometry of Western blots from four repeated experiments, each 
normalized to wild-type HB-IGF-1 binding. mean ± SEM, * vs. WT HB, p<0.005. 
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Figure 4.3. Binding analysis of HB-IGF-1 and IGF-1 to isolated glycosaminoglycans. 
(A) Representative sensorgram for Biacore kinetic analysis over HS or CS surfaces using 
250 nM HB-IGF-1 or IGF-1. HB-IGF-1 is shown in the top two curves (black) with 
corresponding equilibrium binding constants, KD, determined from a minimum of three 
concentrations used during three experimental repeats. IGF-1 (bottom two curves, grey) 
was unable to bind either surface (RU < 10). (B) Sandwich ELISA detecting absorbance 
at a given HB-IGF-1 (solid line, black) or IGF-1 (dashed line, grey) concentration 
resulting from binding HS or CS. Representative of two repeats, each with duplicate 
wells. n=2, mean ± SEM, * vs. CS, p<0.05. 
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Figure 4.4. Retention of HB-IGF-1 in vivo. Western blot showing retained IGF-1 (I) or 
HB-IGF-1 (HB) in rat cartilage, meniscus, patella, patellar tendon, or muscle extracts one 
day after intra-articular injection of IGF-1, HB-IGF-1, or saline. 
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Figure 4.5. Retention of HB-IGF-1 in human cartilage explants. Human cartilage (grade 
0 to 2) was incubated with HB-IGF-1 or IGF-1 for two days (Day -2 to 0), washed, and 
incubated in IGF-free medium for 4 days (Days 0-4). (A) Amount of HB-IGF-1 or IGF-1 
remaining in cartilage after 0-4 days. The experiment was performed on cartilage from 
four donors and a representative Western blot is shown. (B) Analysis of four Western 
blots by densitometry, normalized to the density of 5 ng of the respective protein standard. 
mean ± SEM, * vs. IGF-1, p<0.05. 
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Chapter 5. Conclusions and Future Directions 
 
The inability of articular cartilage to repair itself after acute injury has been implicated in 
the development of osteoarthritis. Providing anabolic stimulation through delivery of 
growth factors may improve the ability of endogenous and exogenous cell sources to 
initiate repair. Additionally, providing a chondrogenic microenvironment may further 
stimulate repair by native or delivered bone-marrow-derived stromal cells. The objective 
of this work was to develop methods for delivering growth factors to cartilage and to test 
the ability of a self-assembling peptide scaffold, (KLDL)3, with or without growth factors 
to augment repair. Delivery methods included growth factor adsorption, scaffold-
tethering, and modification of growth factor structure. 
 
In Chapter 2, two different modes of growth factor delivery were investigated: adsorption 
and tethering. IGF-1 and TGF-β1 were pre-mixed with the self-assembling peptide 
hydrogel, (KLDL)3 or KLD, solution to adsorb the growth factors to the scaffold during 
the assembly process. Biotinylated versions of the growth factors were tethered to the 
peptide through streptavidin and biotinylated KLD. Adsorption was able to deliver TGF-
β1 in sufficient quantities to induce chondrogenesis of bone marrow derived stromal cells 
(BMSCs); IGF-1 diffused too quickly out of the scaffold to stimulate extracellular matrix 
production by chondrocytes. Additionally, while tethering these factors through a biotin-
streptavidin bond provided long-term sequestration, tethered growth factors were not 
effective in stimulating proteoglycan production. Therefore, while self-assembling 
peptide sequences are readily functionalized, the manner in which growth factors are 
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delivered affects bioactivity and varies for specific growth factors and biological systems 
of interest.  
 
To improve tethering, one could use a lower affinity tethering system to allow reversible 
tethering, or one could incorporate cleavable links in the peptide sequence. For instance, 
one could use an MMP- or ADAMTS- cleavable link before the growth factor linkage, so 
that upon upregulation of these enzymes the growth factor would be released. 
 
In Chapter 3, the self-assembling peptide hydrogel KLD with or without chondrogenic 
factors and allogeneic BMSCs was evaluated in a full-thickness, critically sized rabbit 
cartilage defect model for ability to stimulate cartilage repair. Delivering KLD alone 
resulted in improved filling of osteochondral defects and improved cartilage repair, as 
seen by cumulative histology score, Safranin-O staining, and type II collagen 
immunostaining. In this small animal model, the full-thickness defect provided access to 
the marrow, similar in concept to abrasion arthroplasty or spongialization in large animal 
models (goat, sheep, horse, human), and suggests that combining KLD with these 
techniques may offer an improvement over current practice. Ongoing studies include the 
evaluation of KLD in a clinically relevant sized equine defect co-treated with 
microfracture and subjected to strenuous exercise, compared to defects treated with 
microfracture alone. 
 
Even though the chondrogenic factors and BMSCs selected for this study proved 
sufficient to induce chondrogenesis in vitro, they did not have the intended effect when 
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delivered in vivo, highlighting the necessity of further in vivo testing. The length of time 
the peptide hydrogel is present in the defect and the degradation kinetics should be also 
addressed in future in vivo and in vitro studies.  
 
In Chapter 4, it was shown that adding a heparin-binding motif to IGF-1 converts this 
protein from a short-acting growth factor to one that can be locally delivered and retained 
in articular cartilage in vivo. HB-IGF-1 does not require heparan sulfate for retention in 
either cell culture or in cartilage explants. While HB-IGF-1 does have a higher affinity 
for heparan sulfate, its affinity for chondroitin sulfate is within an order of magnitude. 
Therefore, in cartilage, where CS concentrations are found to be 500-1000 times higher 
than HS, binding to CS dominates and retention of HB-IGF-1 is independent of HS.  
 
These results led to the hypothesis that HB-IGF-1 could be preferentially delivered and 
retained in articular cartilage due to its high concentration of sulfated 
glycosaminoglycans. This hypothesis was tested in rats in vivo, and it was shown that 
after intra-articular injection, HB-IGF-1 remained bound to the CS-rich articular 
cartilage, but not to the adjacent patella, patellar tendon, or muscle tissue. In contrast, 
unmodified IGF-1 was not able to bind either CS or HS, and was not detectable in either 
tissue after intra-articular injection. Finally, it was demonstrated that HB-IGF-1 was 
retained in adult human cartilage, whereas unmodified IGF-1 is not. Taken together, the 
results suggest that modification of growth factors with heparin-binding domains may be 
a clinically relevant strategy for local delivery to cartilage. Ongoing studies focus on 
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evaluating the ability of HB-IGF-1 to promote proteoglycan synthesis in rat cartilage ex 
vivo following intra-articular injection. 
 
While injection of the protein alone has been shown to be adequate to deliver HB-IGF-1 
to cartilage for up to four days, and sustained proteoglycan synthesis for up to eight days, 
to attain longer-term delivery, a carrier may be necessary. One option would be to use a 
hydrogel such as KLD with incorporation of chondroitin sulfate or heparan sulfate to 
increase binding and modulate the release kinetics. Another option would be to 
encapsulate HB-IGF-1 in polymer microspheres and deliver the microspheres in a 
hydrogel to the joint. In addition, radiolabel studies with 125I-HB-IGF-1 will enable better 
characterization of the uptake into KLD and the further delivery into cartilage tissue.  
 
In conclusion, the work in this thesis provides a basis for future growth factor delivery 
studies in the context of cartilage and suggests that the self-assembling peptide KLD and 
the fusion protein HB-IGF-1 may be further developed to aid in cartilage repair. 
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Appendix A – Protocols and data related to Chapter 2 
 
Encapsulating cells in KLD with or without biotin-streptavidin tethering of growth 
factors 
 
Use tissue-culture treated 24-well plates if using chondrocytes, non-tissue cultured if 
using BMSCs (BMSCs tend to crawl out of the gels and stick to the bottom of tissue-
culture treated plates). 
 
Agarose ring molds: 
Fill wells of a 24-well plate with 0.6 mL of 2-3% sterile low-melting point agarose. 
Let agarose solidify at 4 °C for a few hours. 
In the hood, use a sterile 6 mm punch to make holes in the center of each well. 
Use a sterile spatula to remove these holes. 
Use a sterile 12 mm punch to make holes centered around the 6 mm holes you just 
created. 
Again, use a sterile spatula to remove the agarose around the hole you just punched so 
you are left with a ring with an outer diam of 12 mm and an inner diam of 6 mm. 
 
Casting with KLD: 
 
You will need the following solutions: 
10% sterile sucrose 
10% sterile sucrose + 2.5 mM HEPES 
HGDMEM + 25 mM HEPES 
Culture medium (usually 1% ITS+1 with HGDMEM unless doing IGF-1 experiments, 
then mini ITS+1 (0.003% ITS+1)) 
 
And the following materials: 
KLD (6 mg per round of casting) 
For tethering: biotinylated KLD (bKLD), streptavidin, biotinylated IGF-1 (bIGF-1) 
2 mL tubes with 0.9 mL Tris buffer in them 
Repeat pipettor with a 1 mL sterile syringe for each round of casting 
 
Fill the wells of the 24-well plate with HGDMEM+HEPES so that the rings get saturated 
with medium in order to aid in self-assembly of the peptide. 
Resuspend KLD at 4.5 mg/mL with sterile 10% sucrose. If tethering, you may want to 
increase this to 4.6 mg/mL to account for the extra volume you will be adding. For 
this protocol, I am assuming a final concentration of ~3.5 mg/mL. You can safely use 
a final concentration in the range of 3.2 – 4 mg/mL. Sonicate for about 60 min, 
vortexing and spinning down intermittently. 
If tethering, resuspend bKLD at 2 mg/mL with sterile 10% sucrose. Sonicate for at least 
30 min – bKLD at this concentration goes into solution much faster than KLD. 
When KLD is in solution, transfer 1.2 mL to a polypropylene 5 mL tube for each round 
of casting you plan to do. (1.165 mL if tethering). Put tube in sonicator. 
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If tethering, add 27 uL bKLD to each tube (1:100 concentration of bKLD:KLD). 
Pre-mix streptavidin and bIGF-1 in equimolar amounts. If you want 300 ng/mL bIGF-1 
inside the peptide, combine 4.5 uL of bIGF at 100 ug/mL and 3.34 uL of streptavidin 
at 1 mg/mL. Add this mixture to your peptide tube with bKLD in it about 5-15 
minutes before casting. (If you want to adsorb growth factors, you would just add 
your growth factor directly to the peptide mixture at this point without including the 
streptavidin or bKLD.) 
When all peptide tubes look like they have a low viscosity and few bubbles, spin down 
your tube of cells (200g for 8 min for chondrocytes, 100g for 5 min for BMSCs). 
While the cells are spinning, aspirate the medium out of the centers of your agarose rings 
in your 24-well plates. Make sure that the rings are not leaking. If they are, just 
remove all of the medium from the well. 
When the cells are finished, aspirate the supernatant and resuspend your cells in 0.3 mL 
of sucrose+HEPES. Make sure the pellet is broken up completely as cell clumps 
generally result in death. 
Pull up all of the cells and put them into your peptide tube. Use your thumb to cover the 
top of the tube and vortex gently and briefly (~ speed 4) to homogenize the cells and 
peptide mixture. 
Pull up the cell/peptide solution in your repeat pipettor set to 50 µL. Click the dispenser 
button once so that the volume numbers stop blinking. 
Now quickly put 50 µL of cells/peptide in the middle of each ring (generally get 19-20 
gels per round of casting). 
When you are finished, use a P200 to put 50 µL of leftover cell/peptide solution in tubes 
containing 900 µL Tris buffer for use as day 0 DNA standards. 
About 2-5 minutes after casting, you should put either HGDMEM+HEPES or culture 
medium in all of your wells so that the gels finish assembling and the pH is 
neutralized. 
Repeat this process for the remaining rounds of casting. 
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 Dose-response with soluble IGF-1 and bIGF-1 on chondrocytes encapsulated in 
KLD 
 
 
 
Figure A1. Effect of soluble IGF-1 and bIGF-1 on sGAG and DNA content of 
chondrocytes encapsulated in KLD. Chondrocytes were encapsulated in KLD and 
cultured for 4 days in soluble IGF-1, soluble bIGF-1, or 1% ITS+1. Treatments were 
started on day 1 post encapsulation. sGAG and DNA content per gel are shown. 
mean±SEM. n=4. 
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Figure A2. Effect of soluble IGF-1 and bIGF-1 on 35S-sulfate incorporation of 
chondrocytes encapsulated in KLD. Chondrocytes were encapsulated in KLD and 
cultured for 4 days in soluble IGF-1, soluble bIGF-1, or 1% ITS+1. Treatments were 
started on day 1 post encapsulation; Radiolabeled on day 4; Ended experiment on day 5. 
mean±SEM. n=4. 
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Effect of tethered IGF-1 on BMSCs encapsulated in KLD 
 
 
Figure A3. Effect of tethered bIGF-1 on BMSCs encapsulated in KLD. TGFβ-1 (100 
ng/mL) and dexamethasone (100 nM) were adsorbed to KLD gels with or without 300 
ng/mL biotinylated-IGF-1/streptavidin/biotinylated-KLD. (A) sGAG retained in the 
hydrogels. (B) DNA content of the hydrogels. (C) 35S-sulfate incorporation over the last 
24 hours. (D) 3H-proline incorporation over the last 24 hours. n=16 (3 animals, 4 
experiments, n=4 per experiment). mean ± sem. * vs. Day 14, † vs. Day 21, p<0.05 
(linear mixed model with animal as a random factor on log transformed data). 
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Flow Cytometry 
Invitrogen - #V13241 – Vybrant Apoptosis Assay Kit #2 
Accuri C6 Flow Cytometer – Schauer and Lauffenburger labs each have this machine 
Can reuse and autoclave syringe filters and plastic filter holders 
PI (propidium iodide, red fluorescence): >670 nm (FL3) 
AlexaFluor 488-Annexin V: 488 nm (FL1) 
 
Some annexin binding buffer comes with this kit, but you can make more of your own: 
ABB Recipe (500mL) - 10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4 
1.192g HEPES 
4.0908g NaCl 
0.184g CaCl2*2H2O 
~2mL of 2M NaOH 
 
1. Assemble syringes/filters by putting a filter between a top and bottom plastic part and 
screwing them together. Put this on the bottom of a 1 mL syringe with the plunger 
removed. 
2. Transfer 1-2 gels from the same condition to 1 mL syringe. 
3. Add 300-500 µL PBS to wash the gel(s) down and push them through the syringe with 
the plunger. Collect the output in a large Eppendorf tube. You can use more PBS if 
necessary, the important part is to get the gel(s) washed down and in liquid so that when 
you push the plunger through, the gel is actually pushed through the filter and not getting 
stuck to the sides of the syringe. 
4. Centrifuge the large Eppendorf tube at 200g for 8 min. 
5. Keep pellet (cells). Some of the peptide will collect near the pellet but still in the 
supernatant, so you can discard that. 
6. Reconstitute with ~400 µL annexin binding buffer to get ~1x106 cells/mL. You should 
count the cells the first time you do this and optimize it for your experiment. 
7. Put 100 µL of each sample in new Eppendorf tube. 
8. Add 1 µL of working stock PI to each tube. 
9. Add 3 µL AlexaFluor488-Annexin V to each tube. 
10. Use leftover cells to make up 3 types of controls: 
a) Combine equal amounts of each type of sample into 3 tubes for total of 100  
uL/tube. 
b) Keep one control unstained. Stain one control with red only. Stain one control  
with green only. 
11. Vortex lightly to mix. 
12. Stand at room temp for 15 min in the dark. 
13. Add 0.4 mL annexin-binding buffer to each tube. Keep samples on ice. 
14. Run through flow cytometer. Run controls first to set gates and adjust the 
compensation. You should not have to adjust the compensation more than a few % to get 
the green control samples all in the lower right quadrant instead of some in the upper 
right quadrant. Keep some cell only samples (cells that were never encapsulated in 
peptide) if possible to identify what is peptide and what is cells in the side scatter vs 
forward scatter plot. 
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15. Population should separate into 3 quadrants: lower left = alive; lower right = green, 
apoptotic; upper right = red and green, dead. 
 
Example pictures of side vs forward scatter plots: 
 
 
Three controls, FL3 vs FL1 plots: 
 
And looking at the chondrocyte gate for the staurosporine positive control: 
 
Figure A4. Example flow cytometry images. 
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Figure A5. Effect of casting order on cell death. There was a slight increase with time, 
but overall it seems the largest variability is between different rounds of casting and with 
cell density. 
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Figure A6. Chondrocytes encapsulated in KLD with or without tethered IGF-1 were 
evaluated for cell death and apoptosis by staining with propidium iodide and annexin v 
and performing flow cytometry at days 1, 2, 3, and 6 post encapsulation. Medium was 
supplemented with No IGF-1, soluble IGF-1 (300 ng/mL), or staurosporine (1 µM). mean 
± SEM. n=5 experiments (2 gels averaged for each experiment) for day 1. n=2 for day 2. 
n=4 for day 3. n=1 for day 6. Day 1 values ranged from 20-41% death for no IGF-1. 
Intra-experiment variation was <3% per condition. Stats: ANOVA on days 1 and 3 data 
with Tukey post-hoc, * vs. staurosporine, p<0.05. 
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Casting Alginate Beads with Cells 
Adapted from Delphine Dean and Bobae Lee. 
 
Autoclave: 
• 50 mL beaker 
• 3-500 mL bottles (for solutions below) 
• 1 spatula (to move beads) 
 
Solutions: 
• 2% alginate in 0.9% NaCl 
• 0.9% NaCl: 9 g in 1000 mL DI water 
• 150 mM NaCl (FW 58.44): 4.38 g in 500 mL DI water 
• 102 mM CaCl2 (FW 111) in 0.9% NaCl: 5.66 g CaCl2 in 500 mL of 150 mM 
NaCl 
• 55 mM Na Citrate (FW 294.10) in 150 mM NaCl: 8.09 g Na Citrate in 500 mL of 
150 mM NaCl 
 
Filter all solutions through a 200 µm filter and into the sterile bottles. 
 
To make the beads 
1. Fill the sterile 50 mL beaker with 30 mL of 102 mM CaCl2 solution. 
2. Get a cell count of cells using the hemocytometer. Spin cells down (if needed). 
1800 rpm, 10 min. Suction off supernatant (being careful not to suck up any 
cells.) Gently tap bottom of vial to break up cells. May need to add 1 mL sterile 
PBS (no Mg++ and Ca++, pH 7) to help break up the cells. 
3. Add appropriate amount of alginate. [ideal conc: 10-15x106 cells/mL; can be as 
high as 20x106 cells/mL] (I did 20 million cells/mL and it worked fine.) 
4. Use 16G needle and 3 mL syringe to suction up the alginate-chondrocyte solution. 
Remove as many air bubbles as possible from the syringe. 
5. Remove 16G needle and replace with 22G needle. Hold the syringe at a 45° angle 
with the hole facing downward.  
6. With steady pressure, drop even-sized droplets into the CaCl2 solution. Halfway-
through you may want to exchange the CaCl2 solution with fresh solution so the 
Ca++ does not get depleted.  
7. After 10 minutes, suction off the CaCl2 and rinse twice with 20 mL sterile PBS 
(no Mg++ and Ca++). Let each rinse go for 1 min. (Note: CaCl2 + PBS causes a 
precipitate to form, so only do 1 min rinses or use DMEM instead of PBS.) 
8. Replace PBS with culture medium.  
9. Fill a 12-well plate with 2 mL culture medium in each well. Using a sterile 
spatula, transfer 6-8 beads/well.  
10. Do a cell viability assay on one of the beads.  
11. Keep alginate-cell beads in an incubator.  
 
To dissolve the beads – I used the first method 
1. Put 4 beads into a 1.5 mL eppendorf tube. Add 1.2 mL NaCitrate. Place in a 37 °C 
water bath or incubator for 10 minutes. Shake gently to mix. Do not vortex. 
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2. Spin 3000-4000 rpm (~1000 rcf) in Eppendorf centrifuge 5415C for 5 minutes.  
3. Remove supernatant. Add 1 mL 0.9% NaCl. Centrifuge 3000-4000 rpm, 5 min. 
Repeat.  
4. Resuspend final pellet in PBS (if doing a cell viability assay) or culture medium at 
desired concentration (~0.5 ml -> gave me about 1 million cells/mL).  
5. Do a cell viability assay – should get <5% dead.  
 
OR 
1. Put 15 beads into a 15 mL conical tube. Add 5 mL NaCitrate. Place in 37  °C 
water bath for 10 minutes. Shake gently to mix. 5 more minutes with frequent 
shaking if the beads are not dissolved. Do not vortex. 
2. Spin <1000 rpm (with CBE centrifuge) for 6 min. 
3. Remove supernatant. Add 3 mL of 0.9% NaCl to rinse. Spin <1000 rpm. 
Resuspend in medium. 
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 TUNEL staining (courtesy of Dr. Bodo Kurz, University of Kiel) 
 
 
Figure A7. TUNEL staining on chondrocytes encapsulated in KLD. Percent 
chondrocytes stained positive for TUNEL when encapsulated in KLD with or without 
tethered bIGF-1. Cells were incubated in No IGF-1, IGF-1 (300 ng/mL), or staurosporine 
(1 µM). Day 3 post encapsulation. Gels were fixed in 10% formalin overnight, paraffin 
embedded, and shipped to Dr. Bodo Kurz for TUNEL staining. Stats: Mixed model with 
animal as a random factor, n=18 (3 animals), Tukey post-hoc test, mean ± SEM, * vs No 
IGF, † vs Staurosporine, p<0.05. 
 
References below state that TUNEL is not specific for apoptosis and that results must be 
confirmed with morphology. Dr. Kurz has done this by electron microscopy and we have 
determined that the results are more consistent with the flow cytometry data showing no 
difference with soluble IGF or tethered IGF compared to no IGF gels, indicating the 
TUNEL staining was not representative of apoptosis in this case. 
 
Grasl Kraupp B, et al. In situ detection of fragmented dna (tunel assay) fails to 
discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note. 
Hepatology. 21:1465-1468, 1995. 
 
de Torresa C, et al. Identification of necrotic cell death by the TUNEL assay in the 
hypoxic-ischemic neonatal rat brain. Neuroscience Letters. 230:1-4, 1997. 
 
Kelly K, et al. A novel method to determine specificity and sensitivity of the TUNEL 
reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol. 284:C1309-C1318, 
2003. 
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Western blots on cells encapsulated in peptide hydrogels 
Adapted from Diana Chai and Nora Szasz protocols 
 
Gel Lysis Protocol 
 
Lysis Buffer:  
50mM Tris/HCl, pH 7.2 (0.151375g in 25mL) 
150mM NaCl (0.21915g in 25mL) 
10mM EDTA (0.09306g in 25mL) 
1% Triton X-100 (0.25mL) 
1% equiv of NP-40 (0.25mL) 
-Sonicate to dissolve. 
-Day of add the following to 0.85 mL of lysis buffer:  
10 µL Na3VO4 (0.7356 g/20mL dH2O pH 10 for 20 vials of 100x)  
100 µL NaF (0.8398 g/20mL dH2O for 20 vials of 10x) 
40 µL protease inhibitor cocktail (stock at 25x) 
 
1. Rinse each peptide gel with ice-cold PBS. 
2. Put each gel in a large eppendorf tube with 30 µL lysis buffer in it and mechanically 
break up by pipetting up and down.  
3. Sonicate briefly, sit on ice for 15 min. 
4. Centrifuge at 10000g for 10 min. 
5. Freeze supernatant. 
 
Run a BCA assay to determine the total protein content in the gel. Try up to a 1:10 
dilution. 
 
Western blot 
Use 15 well (1.5mm thick) Invitrogen bis-tris gel. 
Choose the % gel and MOPS/MES buffer depending on the MW of your protein of 
interest. 
Can run up to 25 µL per well. 
For each sample: 
5 µL – 4x running buffer 
2 µL – 10x reducing agent 
up to 13 µL sample (load equal amounts of total protein, typically ~10-15 µg) 
- I like to make a stock of 4x running buffer and reducing agent and then add 7 µL to 
each of my samples. 
 
After prepping samples, boil for 5 minutes, spin down, and load into your gel. 
Run at 200 V for 30-45 min. If apparatus heats up, can surround with ice or run at 4 °C. 
 
Transfer for 60 minutes @ 70V (time and voltage may change depending on protein of 
interest) with stir bar in cold room in transfer buffer without SDS (3.03 g tris base + 14.4 
g Glycine, 200 mL methanol). (Can add 0.1% SDS and reduce methanol to 10% if 
transferring large proteins >80 kDa). Use PVDF membrane in most cases. 
126 
 
Block for 1 hr in 5% milk+PBST (or TBST) at room temp on shaker plate. 
Incubate gel in 1:500 to 1:1000 primary antibody overnight at 4 °C on shaker plate.  
The following day, wash in PBST 3x10 min at room temp on shaker plate. 
Incubate in secondary anti-species of your primary antibody (1:2000) for 1 hr at room 
temp on shaker plate. 
Wash in PBST 3x10 min or longer last rinse if high background is an issue at room temp 
on shaker plate. 
Image with chemiluminescent kit. 
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Figure A8. Phospho AKT and phospho ERK Western blots. Chondrocytes were 
encapsulated in KLD with or without 300 ng/mL tethered IGF-1 (bIGF). Gels were 
cultured in No IGF-1 (No and bIGF) or 300 ng/mL IGF-1 (IGF) supplemented medium 
for 1, 2, 3, or 6 days post encapsulation. BMSCs were encapsulated in KLD with 100 
ng/mL TGF-β1 and 100 nM dexamethasone adsorbed to the scaffold (SDT+dex) with or 
without 300 ng/mL tethered IGF-1 (bIGF). Gels were cultured in basal medium for 7 
days post encapsulation. At each timepoint, gels were lysed and protein measured by 
BCA assay. Equal amounts of protein were loaded (5-10 µg) and a Western blot for 
either (A) pAKT (Cell Signaling #9271) or (B) pERK (Cell Signaling #9101) was 
performed. Membranes were stripped and reprobed for either AKT (Cell Signaling 
#9272) or ERK (Cell Signaling #9102). 
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Appendix B. Protocols and data related to Chapter 3 
 
 
Figure B1. Circular dichroism spectroscopy to confirm secondary structure of the peptide 
and to monitor assembly. Top: Dissolved KLD in 10% sucrose to 0.35 mg/mL. Added 2 
or 5 µL of 0.2 N NaOH to 200 µL KLD solution to get pH 7.5 and 9, respectively. As pH 
increases, the peptide self-assembles. Bottom: 25 µL of PBS was added to 275 µL of 
0.35% RAD. 
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In situ peptide assembly 
 
Made 4 defects, front two were subchondral (5 mm diam), back two were 5 mm diam x 2 
mm deep cartilage-only defects with vertical edges. 
 
 
Figure B2. In situ peptide assembly and cell viability. Used 2 peptide concentrations for 
subchondral defects, front-most one was 6.3 mg/mL, back one was 3.5 mg/mL. At 5 min, 
starting to gel but still liquid. At 8 min, the 6.3 mg/mL gel was assembled. At 12 min, the 
3.5 mg/mL gel was assembled. (Used 2 µL of Coomassie blue to make the peptide purple 
in order to see it in the defect.) These gels stayed in the defect even after tilting the joint 
to fill the other defects. PBS did not wash the gels out. Used 2 peptide concentrations for 
non-chondral defects, front one was 6.3 mg/mL but we added 100 µL more sucrose to it 
since starting to clump in falcon tube, ended up looking like original 6.3 mg/mL but 
actually probably more like 4 mg/mL. Back defect was 3.5 mg/mL. At 8 min, both 
defects had assembled nicely and did not get disrupted by stream of PBS or by 
articulation of joint. Chondrocytes in KLD survived this procedure (Lower right). 
 
Notes: 
Blood from subchondral defect did not affect self-assembly process but these were not 
actively bleeding defects, so this may not reflect the surgical situation. 
Able to self-assemble KLD in 8 min and flow PBS over gels without displacement. 
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Joint Articulation/KLD retention study 
 
 
 
Figure B3. In situ filling and joint articulation using 4 mg/mL KLD with Trypan blue. 
Made 15 mm square defect, 1.5 mm deep on trochlear groove of bovine. Filled to edge of 
defect. Dripped in PBS to initiate self-assembly. Lubricated joint surface (not defect area) 
with PBS. Articulated joint 3 times and KLD remained in defect. Additional 3 
articulations had no effect on KLD. Upper left, before fill; Upper right: fill; Lower left: 
after articulations. 
 
Figure B4. In situ filling and joint articulation using 3.2 mg/mL KLD with Trypan blue. 
Did same as above and peptide stayed in defect, but didn’t seem as sticky as 4 mg/mL. 
Left: fill; Right: after articulation. 
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Other conditions of Rabbit Study 
 
Table B1. Treatment groups not included in Chapter 3. 
 
Condition n KLD BMSCs TGF-β1 bIGF/dex HA 
4 (left) + + 1.4 ng + - 
4 (right) 7 + + 0.7 ng + - 
5 (left) - + - - + 
5 (right) 6 - - - - + 
 
 
 
Figure B5. Gross necropsy photographs of joints in Groups 4 and 5. 
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Figure B6. Gross and histologic effects comparing defects treated with 
KLD+BMSCs+1.4 ng TGF-β1 in group 3 to defects treated with the same combination in 
group 4. Defects in group 3 had contralateral empty defects while defects in group 4 had 
contralateral defects treated with KLD+BMSCs+0.7 ng TGF-β1. 
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Figure B7. Immunohistochemistry scores (0-4). A) Aggrecan. B) Collagen II. C) 
Collagen I. * p<0.05. 
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Results: Radiographic analyses pre- and post-treatment did not reveal any differences 
among groups 1-3, but comparing treated defects in group 3 to the 100 ng/mL TGF-β1 
defects in group 4 showed more radiographic pathology for the group 4 knees (p<0.057) 
demonstrating higher amounts of lysis, bony proliferation, osteophyte formation and 
patellar luxation in that group. 
 
Upon necropsy, joints in groups 1-3 and 5 appeared normal, while three rabbits that 
received treatments in both knees (group 4) had mild to severe inflammation. Group 4 
also demonstrated bony proliferation along the trochlear ridges and patellar luxation. 
Those receiving an intra-articular injection of BMSCs in one knee (group 5) also showed 
mild osteophyte formation, while rabbits with both knees treated (group 4) had mild to 
moderate osteophyte formation. Comparing group 3 and group 4 defects treated with the 
same amount of TGF-β1 (100 ng/mL), group 4 revealed significantly worse repair based 
on total grade (the overall quality of the repair tissue taking into account all observed 
factors) (p<0.019), color (p<0.019), and synovial membrane (p<0.0496), while incision 
appearance, inflammation and swelling, and articular surface integrity approached 
significance (p<0.055). 
 
Within group 4, comparing the defect with 50 ng/mL TGF-β1 to the contralateral defect 
receiving 100 ng/mL TGF-β1, there were no significant differences for any of the scores. 
Defects receiving an intra-articular injection of BMSCs (group 5) appeared more yellow 
in color than those receiving HA alone (p<0.028). 
 
Similar to gross evaluation, there were no significant differences within group 4. Knees 
with 100 ng/mL TGF-β1 in group 4 had worse repair tissue than treated defects in group 
3 with more hypocellularity (p<0.055) and less repair tissue thickness (p<0.064). There 
were no significant differences within group 5, although the nature of predominant tissue 
and reconstitution of subchondral bone scores trended towards a worse repair for the 
BMSC-treated defects (p<0.07). 
 
Comparing group 3 treated defects to group 4 defects with 100 ng/mL TGF-β1, collagen 
II scoring was not significant, but trended (p<0.1) towards higher scores for group 3. 
Within groups 4 and 5 there were no significant differences. 
 
Discussion: In addition, treating two knees in one rabbit with BMSCs and different doses 
of TGF-β1 (group 4) resulted in an increased inflammatory response and bony reaction, 
as seen by the comparison between this group and the treated defects in group 3 in which 
only one knee received TGF-β1. This finding suggests possible systemic effects of 
treatment and that negative effects were caused by increasing the total body dose of TGF-
β1 (2.25 ng total for rabbits receiving two treatments and 1.5 ng for those with one 
treatment).  Finally, treating defects with an intra-articular injection of BMSCs in HA 
(group 5) offered no advantage over injection of HA alone. 
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Appendix C. Protocols and data related to Chapter 4 
 
Western blot on medium following enzyme treatment of cartilage explants 
HS stub antibody detects cleavage following heparatinase treatment. 
 
Use 4-12% bis-tris 15 well (1.5mm thick) Invitrogen mini-gel. 
Used Novex sharp protein standard from Invitrogen. 
 
Can run up to 25 µL per well. 
5 µL – 4x running buffer 
2 µL – 10x reducing agent 
13 µL conditioned medium 
Boil all samples for 5 min. 
 
Ran Gel in MOPS running buffer at 200V for 45-60 min 
 
Transferred for 80 minutes @ 75V with stir bar in cold room in transfer buffer with 0.1% 
SDS (1 g SDS) and 10% methanol (3.03 g tris base + 14.4 g Glycine, 100 mL methanol). 
Used PVDF membrane. 
 
Antibody Incubation: 
Blocked for 1 hour in 5% milk+PBST. 
Incubated gel 1:500 with 3G10ab (Seikagaku) O/N @ 4 °C .  
 
Following day, washed in PBST 3x10 min. 
Incubated in secondary: 1:1000 Anti-mouse 60 minutes @ RT.  
Wash in PBST 3x10 minutes 
Imaged using chemiluminescence kit. 
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Figure C1. Western blots of conditioned medium following no enzyme (N), heparitinase 
(H), chondroitinase (C), or chondroitinase followed by heparitinase (C+H) treatment of 
cartilage explants. Used anti-HS stub (3G10ab) antibody. 
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Biotinylation of GAGs 
Adapted protocol from: Ute Friedrich, Anna M. Blom, Björn Dahlbäck and Bruno O. 
Villoutreix. Structural and Energetic Characteristics of the Heparin-binding Site in 
Antithrombotic Protein C. J Biol Chem. 276:24122-24128, 2001. 
 
Biotin hydrazide biotinylates GAGs on carboxyl groups. I first attempted to use Sulfo-
NHS-LC-Biotin, which normally biotinylates at the primary amine of proteins, but this 
didn’t seem to work for the GAGs even though others have reported doing it this way. 
 
Pierce EZ-Link Biotin-LC-Hydrazide kit: #21340 
Pierce Zeba Desalt Spin Columns: #89891 
Heparin: Sigma, #H3149 
Heparan sulfate: Sigma, #H7640 
Chondroitin sulfate: Sigma, #C4384 
 
1. Dissolved GAG in 0.1 M MES at 2.5 mg/mL. Used 200 µL (0.5 mg). 
2. Added 12.5 µL of 50 mM biotin hydrazide. (at least 1 mg biotin in 54 µL DMSO). 
3. Added 0.5 µL of 0.5 M EDC. (at least 5 mg in 50 µL MES). 
4. Mix with constant shaking (taped to rotary shaker plate and put on high) O/N at room 
temperature. 
5. Desalt using spin columns and equilibrate in water. I would use 2 different columns to 
make sure you get rid of all the unincorporated biotin. I only used one column and one of 
the times I did this it seemed like I had a lot of free biotin left in my sample when I was 
finished. You can store at 4 °C for at least several weeks. An alternative would be to 
lyophilize and store in -80 °C for long-term storage. 
6. Confirm biotinylation using HABA/Avidin assay or dot blot using anti-biotin. 
 
Sandwich ELISA (biotinylated GAGs attached to streptavidin-coated ELISA plate; 
HBIGF/XIGF in solution; amount bound detected by anti-IGF-1) 
Used KPL ELISA kit (54-62-15) 
 
1. Use pre-coated R&D streptavidin plate (CP003). Coat ELISA plates with 100 µL of 20 
µg/mL biotinylated GAGs in coating buffer. Incubate overnight at 4 °C. Need 6.5 mL 
coating buffer. 
 
2. Block with kit for 15min 
1. Make BSA diluent for rest of steps.  
2. Add 300 µL BSA Diluent/Blocking Solution to each well. 
3. Incubate 15 minutes at room temp, empty plate and tap out residual liquid. 
 
3. Incubate with varying amounts of HBIGF.  
 1. Add 100 µL Standard/Sample to each well. (do 2 wells per sample) 
2. React at room temperature for 1 hour. 
3. Empty plate, tap out residual liquid. 
 
4. Wash plates. 
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1. Fill each well with 1X Wash Solution. 
2. Invert plate to empty, tap out residual liquid. 
3. Repeat 3 - 5 times. 
 
5. Incubate with anti-IGF for 1 h at 10 µg/mL at room temp. 
1. Add 100 µL Detection Antibody Solution to each well. (anti-IGF at 10 µg/ml)  
2. React 1 hour, room temperature. 
3. Empty plate, tap out residual liquid and wash as above. 
 
6. Wash plates. 
7. Incubate with anti-rabbit HRP for 1 h at 1:500 at room temp. 
1. Add 100 µL Secondary Antibody Solution to each well. 
2. React 1 hour, room temperature, in dark. 
3. Empty plate, tap out residual liquid and wash as above. 
4. Give final 5 minute soak in Wash Solution; tap residual liquid from plate. 
 
8. Wash plates. 
9. Read Substrate 
1. Dispense 100 µL Substrate Solution into each well. 
2. After sufficient color development (read every 1 min), add 100 µL  
Stop Solution to each well. 
3. Read plate with plate reader at 405 nm. 
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Surface Plasmon Resonance (Biacore) Protocols 
 
Conditioning Buffer: 
1M NaCl in 50 mM NaOH. 
 
Running Buffer: 
0.01M HEPES pH 7.4 -> 1 mL in 100 mL 
0.15M NaCl -> 0.8766 g 
3mM EDTA -> 0.111672 g 
0.005% Tween20 -> 5 µL 
Filter and Degas. 
 
Regeneration Buffer: 
1M NaCl in PBS, pH 7.4 
 
Start-up Protocol: 
Load chip. 
Put in Running Buffer. 
Dock. 
Prime, ignore errors. 
 
Shutdown Protocol: 
Undock. Take out chip, store in 50 mL conical with 2 mL water in bottom at 4 °C. 
Put in maintenance chip. Dock. 
Put tubes in water instead of running buffer. 
Prime into water (7 min). 
Fill 2 vials with 3 mL SDS (1) or 3 mL glycine (2). Put in rack. 
Run desorb (22 min). 
Prime water 2x. 
Take out water. Put in kim wipe. Prime with air. 
Undock. 
Take out maintenance chip. 
 
First run, attach GAGs to chip: 
Run sensorgram. Fc-1-2-3-4 measure all 4. 
Switch to Fc-4. Flow 20 µL/min. NaOH 3x 1min. 
Wash needle 2x. 
Manual inject. Load bHeparin, 26 µL in F4, saturated at 10 µL. 
Switch to Fc-3. Quick inject 20 µL NaOH 3x. 
Wash needle 2x. 
Switch to 5 µL/min. Load bHS, saturated in few µL. 
Switch to Fc-2. 
Flow 20 µL/min NaOH 3x1min. 
Wash needle 2x. 
Flow 10 µL/min. Manual inject. Load bCS, saturated at 5 µL. 
Switch to Fc-1. 
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Flow 20 µL/min. Quick inject 20 µL NaOH 3x. Wash needle 2x. 
Put 1 µM (90 µL) HBIGF. Switch to Fc-1-2-3-4. 5 µL/min. 
KinInject 25 µL = 300 s. Dissoc 300 s. 
Put in 0.1M NaCl in PBS. Change to 20 µL/min. 
Quick inject 20 µL x2. 
Wash needle 2x. 
Switch to 5 µL/min. Put in 100 nM (70 µL) HBIGF. 
Kininject 25 µL = 300 s. Dissoc 300 s. 
20 µL/min. Quick inject 0.1M NaCl in PBS. 20 µL 1x.  
 
To acquire kinetic data: 
Docked chip. Primed into RB. 
Run 1: Flow rate 20 µL/min. Run with RB. Quick Inj 1M NaCl in PBS. Run with RB. 
Run 2: 100 nM fresh HBIGF at 20 µL/min for 300 s. Dissociation 300 s. 
 Quick Inj 2x with 1M NaCl 20 µL. 
 Wash needle 2x. 
Run 3: 250 nM HBIGF 
Etc. 
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Densitometry (semi-quantitative analysis of Western blots) 
 
with FluorChem software program:  
Hit cancel when it asks for a serial number. 
Make sure your file name is short or the file will not open. 
On the contrast enhancement panel, hit reverse and auto contrast to view your gel. You 
can further adjust the black, white, and gamma channels to improve your view. Doing 
this does not affect the pixels the software program uses to calculate density. 
On the toolbox panel, choose the Analysis Tools tab. Then choose the Spot Denso tab. 
Make sure that if you select a band and select background that the background has a 
lower value. If this is not the case, click the invert button. In most cases, when you 
are starting with a black gel with white bands, you should not have to select invert. 
Use the object buttons to outline each band you wish to analyze separately. 
If you have different amounts of background on your gel, also draw small boxes under 
each band of interest using the background buttons. Then select the background box 
and corresponding band box while holding the shift key. Hit link bkgd. This should 
change both boxes to the same color. 
To copy your data, click output and choose copy to clipboard. 
Paste data into excel. 
The average column = IDV/area. If your boxes are different sizes, you should use the 
IDV column to analyze your data. 
In order to average data from multiple gels, you must have a common condition you can 
normalize to on each gel. 
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Culture of CHO (Chinese Hamster Ovary) Cells  
Adapted from Robin Prince of Rich Lee’s lab 
 
CHO cells grow in F-12 media supplemented with 10% FBS. 
677 cells do not produce heparan sulfate and appear more boxy compared to the CHOK1 
(WT) cells which look more spindle shaped. 
 
Starting culture 
Thaw cells in 37 oC water bath. – Do this fast (2 min or less) 
Put one vial in 10 cm dish with 10 mL warmed F-12 + 10% FBS media.   
Change medium next morning. 
It may take several days for the cells to become confluent. (Because these cell lines are 
very stable it is not necessary to maintain them in drug-containing media). 
  
Splitting confluent cells 
Warm pbs, medium, and trypsin to 37 °C. 
Aspirate off the media from a 10 cm dish of cells. 
Add 2 mL trypsin and let incubate for 5 min at 37 °C. 
Add 8 mL medium to stop trypsin, pipette up and down to de-clump. 
Spin down cells at 125g for 5 min. 
Resuspend in 10 mL medium, pipet up and down. 
Typically split 1:4 or 1:5, can go up to 1:8 safely. 
 
Freezing cells 
You should do this during the first passage to keep your stock. You can take half the 
confluent cells in a 10 cm dish to freeze and replate the rest depending on your needs. 
 
Rinse 10 cm dish with PBS. Put in 2 mL trypsin (37 °C for 5 min). Add 8 mL F12+10% 
FBS to stop. Spin down, resuspend in 10 mL F12+10% FBS. Count undiluted and should 
get ~6 million cells. Take 5 mL (3 million cells) to freeze down and put in a separate 
tube. Spin that down and resuspend in 0.6 mL (5 million cells/mL) of 
F12+20%FBS+10%DMSO. Put in cryovial and put in Mr. Frosty in -80 °C overnight. 
Transfer to liquid nitrogen storage. 
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Appendix D. Luminex Pilot Study 
 
Adapted from Megan McBee and Arek Raczynski of David Schauer’s lab 
 
Joint Extraction on Mice 
Materials:  
We used the Biorad Lysis buffer kit. 
 
1. 500 mM AEBSF (12 mg/100 µL water).   Make 100 µL fresh.  
2. Lysing Solution (from Biorad kit) 
 = 40 µL Factor 1 + 20 µL Factor 2 + 9.9 mL Cell Lysis Buffer. Vortex gently. Add 40 
µL 500 mM AEBSF per 10 mL Lysing Solution. Make 10 mL (for 20 samples) 
3. Diluent = 0.05% Tween-20, 0.1% BSA in PBS. Make 50 mL fresh  
 
Methods: 
1. The joints were harvested by careful dissection to remove all attached tissues 
(particularly muscle). The "whole joint" preparation includes bone ends, patellar without 
proximal muscle, and all intra-articular structures (cartilage, cruciates, synovium, 
meniscus etc) and fluid. This preparation was flash frozen and then pulverized as a single 
sample. If possible, weigh the amount of tissue you collect prior to flash freezing. 
2. Pulverize by 12 hammer blows. 
3. Recover powder to tube and immediately add 350 µL (record known volume) of 
"Lysing Solution" (Reagent 2 above) to sample. Parafilm top of closed tubes to prevent 
any possible leakage. Rotate samples for 1-2 h at 4 °C for extraction. 
4. Centrifuge samples at 4500g for 20 min at 4 °C. 
5. Collect supernatant without disturbing pellet and remove clear supernatant. Weigh how 
much you collect.  
6. Store at -80 °C. 
 
Before doing Luminex Assay: 
1. Thaw samples and perform BCA assay. Refreeze. (We used this to normalize and to 
get an idea of how much sample to load.) 
 
Luminex Assay: 
1. We used the 23-plex mouse cytokine pro kit which includes magnetic beads to be used 
in combination with a magnetic plate washer. It comes with very detailed instructions 
which we followed. We used the same lysis buffer to dilute samples and make up 
standard curves as explained a bit more below. 
 
2. From the BCA assay our samples were in the range of 2.3-4.7 mg/mL which is a little 
on the high side of what to load, but since this was our first try with this we used either 
50 uL straight sample in duplicates or 25 uL sample + 25 uL lysis buffer in duplicates. 
We also used both the high and low PMT standard curves for the same reason that we 
didn’t know what to expect. To use both of the standard curves you have to run the plate 
twice, but we didn’t notice any issues with doing this. 
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In the end, the data we used came from using the undiluted samples and the high PMT 
curves.  
 
3. To make sure that all of the standards and samples were incubated with the beads for 
about the same amount of time, we pipetted everything into a separate 96 well plate and 
then used a multichannel pipet to load the samples/stds onto the actual plate. This will 
make more sense when you read the biorad protocol. 
 
4. Also, you should change tips for everything as the assay is very sensitive. 
 
5. Finally, we used n=3 since this was a pilot study, but this was probably too low to get 
significance on some of the cytokines.  
 
 
 
 
Figure D1. Methods: IACUC approval was given by Rush University. Ten week old 
C57Bl/6 male mice were subjected to a surgical Destabilization-Induced Joint Injury 
(DMM) model developed by Glasson et al. alone, to treadmill (TM) running alone (14 
days 15° incline, 32 cm/sec, 20 min per day, for 2 weeks), or to DMM surgery followed 
by TM running beginning on day 4 post-surgery. For DMM surgery, the anterior medial 
meniscotibial ligament was completely severed. Control mice were subjected to only 
cage activity. At 3 weeks post surgery, mice were euthanized and joints were stained with 
India Ink for gross observations or protein was extracted for Luminex (23-plex mouse 
cytokine kit), n=3. Statistics: Data were log-transformed and analyzed by ANOVA with 
Tukey post-hoc test, p<0.05. Luminex data were normalized to the total protein extracted 
per joint and to the control mice. 
 
